Versatile method for the detection of marker-free precision genome editing and genetic variation

ABSTRACT

The present disclosure provides, inter alia, specially designed DNA adaptors and methods of preparing the same. Methods and kits for carrying out and detecting marker-free precision genome editing and genetic variation using such adaptors are also provided.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application claims benefit of U.S. Provisional Patent Application Ser. No. 62/985,746, filed on Mar. 5, 2020, which application is incorporated by reference herein in its entirety.

GOVERNMENT FUNDING

This invention was made with government support under grant no. GM117064, awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF DISCLOSURE

The present disclosure provides, inter alia, specially designed DNA adaptors and various methods and kits for carrying out and detecting marker-free precision genome editing and genetic variation using such adaptors.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

This application contains references to amino acids and/or nucleic acid sequences that have been filed as sequence listing text file “1035795-000704-seq.txt”, file size of 63 KB, created on Apr. 8, 2021. The aforementioned sequence listing is hereby incorporated by reference in its entirety pursuant to 37 C.F.R. § 1.52(e)(5).

BACKGROUND OF THE DISCLOSURE

Precision genome editing allows the modeling and correction of desired genomic variants containing insertions or deletions of specific nucleotide sequences or changes in single DNA bases (Anzalone et al., 2019; Barbieri et al., 2017; Cong et al., 2013; Dow, 2015; Guo et al., 2018; Liu et al., 2018; Mali et al., 2013; Roy et al., 2018). Precision genome editing can be obtained by CRISPR-dependent homology-directed repair (HDR) of Cas9-induced DNA double-strand breaks (DSBs) (Jasin and Haber, 2016) or result from the use of alternative DSB-free methods, such as CRISPR-dependent base editing, which utilizes cytidine or adenosine deaminases fused to a nickase Cas9 (nCas9) mutant to generate base transitions (Gaudelli et al., 2017; Komor et al., 2016), and prime editing, which employs a reverse transcriptase-nCas9 fusion and a template prime editing guide RNA (pegRNA) to install into the genome a large variety of genomic changes, including transversions, transitions, small insertions and deletions (Anzalone et al., 2019).

Genome editing has been facilitated by the development of accessible and cost-effective methods for the detection of small insertions and deletions (indels) resulting from the repair of Cas9-induced DSBs, such as the T7E1 and Surveyor nuclease assays (Mashal et al., 1995; Qiu et al., 2004; Ran et al., 2013). However, since these methods do not determine the identity of DNA bases, they are ill-suited for the detection of genomic changes introduced by precision genome editing (Germini et al., 2018). Precision genome editing events can be detected by the addition of genomic markers by CRISPR-dependent HDR or prime editing, such as silent mutations that create or disrupt restriction sites, or selectable reporters encoding for antibiotic resistance or fluorescent proteins. However, the use of genomic markers entails an elaborate experimental design that is unique for each targeted site, thus complicating the insertion of the desired genetic modifications. In addition, genomic markers can cause unintended perturbations of coding or non-coding genomic elements. Moreover, marker-based detection methods are not compatible with CRISPR-dependent base editing strategies, which induce single DNA base changes (Rees and Liu, 2018). Alternatively, methods that employ Sanger sequencing or next-generation sequencing (NGS) enable the detection of precise genomic changes without the use of genomic markers (Brinkman et al., 2014; Pinello et al., 2016). However, Sanger sequencing-based approaches suffer from low sensitivity and precision due to variable quality of the sequencing reactions and background signals that often affect the sequencing reads (Brinkman et al., 2014; Brinkman et al., 2018). While NGS-based detection strategies are highly sensitive (Clement et al., 2019; Lindsay et al., 2016; Pinello et al., 2016), they remain expensive and time-consuming, which limits their value for the development of mutant cell lines and animal models and for applications that require a rapid turnaround time, such as the identification of pathogenic variants in certain clinical settings. Therefore, a simple, efficient, inexpensive and rapid method that enables quantitative detection of genetic variants in complex biological systems is needed. This disclosure is directed to meeting these and other needs.

SUMMARY OF THE DISCLOSURE

Genome editing technologies have transformed our ability to engineer desired genomic changes within living systems. However, detecting precise genomic modifications often requires sophisticated, expensive and time-consuming experimental approaches. The present disclosure provides DTECT (Dinucleotide signaTurE CapTure), a rapid and versatile detection method that relies on the capture of targeted dinucleotide signatures resulting from the digestion of genomic DNA amplicons by the type IIS restriction enzyme AcuI. DTECT enables the accurate quantification of marker-free precision genome editing events introduced by CRISPR-dependent homology-directed repair, base editing or prime editing in various biological systems, such as mammalian cell lines, organoids and tissues. Furthermore, DTECT allows the identification of oncogenic mutations in cancer mouse models, patient-derived xenografts and human cancer patient samples; it also allows the identification of genetic modifications incurred in various infectious diseases. Ultimately, DTECT enables the capture of signatures in nucleic acids from any organism including, e.g., viruses such as SARS-CoV-2. The ease, speed and cost efficiency by which DTECT identifies genomic signatures should facilitate the generation of marker-free cellular and animal models of human disease and expedite the detection of human pathogenic variants.

Accordingly, one embodiment of the present disclosure is a DNA adaptor comprising: (a) one strand with sequence of 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCTTCTAAGAATTCGAGCTCGGTACC CG-3′ (SEQ ID NO: 230); and (b) one complementary strand with sequence of 5′-CGGGTACCGAGCTCGAATTCTTAGAAGAGAGACAGAATGCTTCTTACCCGTGCCC CAGNN-3′ with “N” corresponding to A, T, G or C (SEQ ID NOs: 231-246).

Another embodiment of the present disclosure is a method of preparing a DNA adaptor disclosed herein, comprising: (a) synthesizing one constant oligonucleotide with sequence of 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCTTCTAAGAATTCGAGCTCGGTACC CG-3′ (SEQ ID NO: 230); (b) synthesizing one complementary oligonucleotide with sequence of 5′-CGGGTACCGAGCTCGAATTCTTAGAAGAGAGACAGAATGCTTCTTACCCGTGCCC CAGNN-3′ with “N” corresponding to A, T, G or C (SEQ ID NOs: 231-246); (c) mixing the constant and complementary oligonucleotides; and (d) annealing the mixture to obtain the DNA adaptor.

Another embodiment of the present disclosure is a library of DNA adaptors prepared by methods disclosed herein, the library comprises 16 DNA adaptors, wherein each DNA adaptor has a different “NN”.

Another embodiment of the present disclosure is a method for detecting a genetic modification, comprising the steps of: (a) amplifying a genomic locus of interest using a specially designed Type IIS restriction enzyme-tagging primer, comprising: (i) extracting genomic DNA from a biological sample of interest; (ii) synthesizing the Type IIS restriction enzyme-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the Type IIS restriction enzyme-tagging primer and a reverse primer; and (iv) purifying a Type IIS restriction enzyme-tagged genomic amplicon; (b) digesting the Type IIS restriction enzyme-tagged genomic amplicon with the Type IIS restriction enzyme; (c) isolating the smaller DNA fragment containing a genomic signature of interest exposed in a 3′ single-stranded overhang; (d) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment containing the 3′ overhang signature with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (e) amplifying the ligated product to detect the presence of the genetic modification.

A further embodiment of the present disclosure is a kit for detecting a genetic modification of interest, comprising a specially designed Type IIS restriction enzyme-tagging primer disclosed herein, and a library of DNA adaptors disclosed herein, packaged together with instructions for its use.

Another embodiment of the present disclosure is a method for detecting a genetic modification, comprising the steps of: (a) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (b) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (c) isolating the smaller DNA fragment containing a genomic signature of interest produced by AcuI-digestion; (d) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (e) amplifying the ligated product to detect the presence of the genetic modification.

An additional embodiment of the present disclosure is a kit for detecting a genetic modification, comprising a specially designed AcuI-tagging primer and a library of DNA adaptors disclosed herein, packaged together with instructions for its use.

Another embodiment of the present disclosure is a method for quantifying a genomic variant in a biological system, comprising the steps of: (a) obtaining a sample from the biological system; (b) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (c) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing a genomic signature of interest produced by the AcuI-digestion; (e) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (f) quantifying the genomic variant and determining its relative abundance.

Still another embodiment of the present disclosure is a method for identifying and quantifying an oncogenic mutation of interest in a biological sample, comprising the steps of: (a) obtaining a biological sample; (b) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (c) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing a genomic signature of interest produced by the AcuI-digestion; (e) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; (f) amplifying the ligated product to identify the presence of the oncogenic mutation of interest; and (g) quantifying the oncogenic mutation of interest, if present, and determining its frequency.

A further embodiment of the present disclosure is a process for marker-free detection of a precision genome editing event comprising carrying out Dinucleotide signaTurE CapTure (DTECT) on a nucleic acid sequence of interest.

Still another embodiment of the present disclosure is a method for detecting a virus variant of interest, comprising the steps of: (a) obtaining a nucleic acid of the virus variant of interest from a biological sample; and (b) if the nucleic acid is DNA, carrying out Dinucleotide signaTurE CapTure (DTECT) to detect the variant of interest; or (c) if the nucleic acid is RNA, coverting it to DNA by reverse transcription PCR (RT-PCR) and then carrying out DTECT to detect the variant of interest.

BRIEF DESCRIPTION OF THE DRAWINGS

The application file contains at least one photograph executed in color. Copies of this patent application with color photographs will be provided by the Office upon request and payment of the necessary fee.

FIGS. 1A-1C show the identification of targeted dinucleotide signatures using DTECT.

FIG. 1A is a schematic representation of DTECT. The targeted genomic locus containing a hypothetical targeted dinucleotide (N=A, C, G or T; green) is PCR-amplified using a forward AcuI-tagging primer juxtaposed to the targeted dinucleotide and a locus-specific DNA primer (AcuI-tagging primer design and PCR, steps I and II). The AcuI-tagging primer (60 nt) is constituted of DNA sequences complementary to the genomic locus (purple) interrupted by a hairpin containing an AcuI recognition site (green), and a non-complementary DNA sequence (blue). The locus-specific reverse primer (red) is located at a distance >100 bp from the targeted dinucleotide. The obtained PCR product is subsequently cleaved by the AcuI restriction enzyme in a position adjacent to the targeted dinucleotide, resulting in the generation of two DNA fragments of 60 bp and >100 bp (AcuI digestion, step III). The 60 bp fragment containing the exposed signature of the targeted dinucleotide is then isolated using SPRI beads with higher affinity towards >100 bp DNA products (Small fragment isolation, step IV). The 60 bp fragment is then ligated to DNA adaptors containing 3′-overhangs of two bases complementary (specific) or not (non-specific) to the dinucleotide signature (Adaptor ligation, step V). The ligated product is then subjected to PCR amplification for analytical or quantitative detection (Detection PCR, step VI). The approximate time required for each step is indicated.

FIG. 1B shows the schematics of the DTECT adaptor library. Control (green) and mutant (purple) dinucleotide signatures (left panel) are detected using a library of 16 unique adaptors (middle panel). The library contains adaptors with dinucleotides complementary to the control (green) or mutant (purple) signature, as well as non-specific adaptors (blue) (right panel).

FIG. 1C shows the schematics of the positive and negative controls used in DTECT experiments to identify signatures of interest (e.g., mutant allele) in allele populations. In genomic DNA samples containing only the WT dinucleotide signature, the adaptor complementary to the WT dinucleotide signature (green) serves as a positive control, while the adaptor complementary to the mutant signature of interest (purple) and a non-specific adaptor (blue) are used as negative controls. In genomic DNA samples containing a mixture of the WT and the mutant dinucleotide signature, the adaptor complementary to the WT dinucleotide signature (green) is used as a positive control and a non-specific adaptor (blue) serves as a negative control. The adaptor complementary to the mutant dinucleotide signature (purple) is used to detect the presence of the variant of interest and quantify its frequency.

FIGS. 2A-2K show the detection and quantification of dinucleotide signatures using DTECT.

FIG. 2A shows the design of AcuI-tagging primers that allow the capture of two dinucleotide signatures (CC and TT; blue) on opposite DNA strands.

FIG. 2B shows the PCR amplification (22 cycles) of the AcuI-digested DNA products containing the CC and TT signatures shown in FIG. 2A, which have been captured using GG or AA adaptors.

FIG. 2C shows the PCR amplification (22 cycles) of DNA fragments captured as in FIG. 2B with or without dephosphorylation of the AcuI-digested products by the shrimp alkaline phosphatase (rSAP).

FIG. 2D shows the PCR amplification (22 cycles) of DNA fragments captured as in FIG. 2B in the absence or presence of AcuI, DNA adaptors (GG adaptor for signature CC; AA adaptor for signature TT) or T4 DNA ligase.

FIG. 2E shows the schematic representation of the AcuI-tagging primer design for detecting four possible dinucleotide signatures (#1-4) containing the same targeted base (C:G, red) in the PIK3R1 gene.

FIG. 2F shows the detection of the four dinucleotide signatures shown in FIG. 2E by DTECT (18 PCR cycles) using specific (green) and non-specific (blue) adaptors.

FIG. 2G shows the quantification by DTECT of the relative abundance of SMARCAL1, SPRTN and PIK3R1 WT (green) and STOP (purple) dinucleotide signatures in mixtures of WT and STOP alleles at predefined ratios. Graphs (left) represent the correlation between the frequency of WT and STOP variants determined by DTECT and the expected frequency of the same variants in the mixed populations for each of the above 3 genes. Error bars represent the s.d. of independent experiments (n=2). Pearson correlation (r) was determined by comparing expected and DTECT-based frequency. Comparison of the mean frequency of STOP and WT signatures determined by DTECT and their expected frequency is shown in the right panel (n=3 independent genes, SMARCAL1, SPRTN and PIK3R1).

FIG. 2H shows the representation of the AcuI-tagging primers used to detect the WT and STOP alleles of the PIK3R1 gene. The targeted dinucleotides are shown in blue, the edited base is indicated with an asterisk and part of the AcuI-tagging primer sequence is shown in purple.

FIG. 2I shows the PCR amplification (25 cycles) of WT and STOP PIK3R1 alleles (arrow) captured using DTECT from WT:STOP allele mixtures (i.e., 100:0 and 99:1). An adaptor (CG) specific for the WT allele is used as a positive control and a non-specific adaptor (TT) is used as a negative control. An adaptor that captures the STOP PIK3R1 allele (CA) serves as an additional negative control in the reaction containing only the WT allele. Background non-specific PCR products are indicated with an asterisk.

FIG. 2J shows the fold change variation in the frequency of capture of each of the 16 dinucleotide signatures relative to the mean dinucleotide capture frequency. Oligonucleotides containing distinct dinucleotide signatures are captured using specific adaptors. The fraction of captured material is then quantified by qPCR and normalized to the mean value obtained from the capture of all 16 dinucleotide signatures. Error bars indicate the s.d. of 4 independent experiments. Dots represent individual data point.

FIG. 2K shows the fold change variation in the frequency of capture of dinucleotide signatures with 1 A/T+1 C/G, 2 NT or 2 C/G bases relative to the mean dinucleotide capture frequency, determined as described in FIG. 2J. Error bars represent the s.d. of 8 mean values for dinucleotides with 1 NT+1 C/G and 4 mean values for dinucleotides with 2 NT and 2 C/G, as determined in FIG. 2J.

FIGS. 3A-3E show the detection and quantification of precision genome editing by CRISPR-mediated HDR, base editing and prime editing using DTECT.

FIG. 3A shows the schematics of the protocol used to identify genomic changes introduced by CRISPR-dependent HDR, base editing or prime editing. In HDR experiments (blue), HEK293T cells were transfected with Cas9 and sgRNA targeting a gene of interest with or without donor DNA molecules. In base editing experiments (red), HEK293T cells were transfected with BE3 base editors with either control or base editing sgRNAs. Base editing experiments were also conducted in cells stably expressing FNLS-BE3. In prime editing experiments (grey), HEK293T cells were transfected with PE2 with or without pegRNA. Genomic DNA was then extracted from cell populations and subjected to DTECT using adaptors specific for WT (green) or edited (purple) variants.

FIG. 3B shows the identification by DTECT of WT and HDR-edited (R209fs*6) TP53 alleles (top), WT and base-edited (Q223*) FANCD2 alleles (middle), and WT and prime-edited (CTT_ins) HEK3 alleles (bottom). Adaptors specific for the WT (CT, CA, CG; green) or edited (TT, TA; purple) signatures were utilized in DTECT experiments. Captured samples were subjected to analytical (left; 21 cycles) or quantitative PCR (right). In the HDR experiment, cells were transfected with Cas9, sgRNA and an ssODN specific for the TP53 locus with or without the HDR stimulatory factor i53. The ssODN was omitted in control reactions. In the base editing experiment, cells were transfected with BE3 and sgRNA to induce Q223* in FANCD2. In prime editing experiments, cells were transfected with PE2 and pegRNA to introduce a CTT insertion in the HEK3 locus.

FIG. 3C provides the graphical representation of the correlation of DTECT- and NGS-based estimations of the frequency of genetic variants introduced by precision genome editing in human and mouse cells, and mouse intestinal organoids (n=62). Data points in the dashed box (frequency <20%) of the left panel are shown enlarged on the right panel (n=33). Error bars indicate the s.e.m. of 2-5 independent replicates. The source of the edited sample is indicated by distinct colors.

FIG. 3D shows the schematic representation of the experiments conducted to measure the efficiency of precision genome editing in vivo using DTECT. Editing of the mouse liver was performed by hydrodynamic injection of the cytidine base editor (CBE) FNLS-BE3 and an sgRNA to introduce the Pik3ca E545K variant. DTECT (red) and NGS (green) were used to determine the efficiency of editing in the mouse liver sample.

FIG. 3E shows the quantification by DTECT (red) and NGS (green) of the Pik3ca E545K variant introduced by CRISPR-mediated base editing in the mouse liver, as shown in FIG. 3D. Error bars indicate the s.d. of 2 independent experiments. Dots represent individual data point.

FIGS. 4A-4C show the identification of multiple genome editing events in a single locus or distinct loci by DTECT.

FIG. 4A shows the detection by PCR (21 cycles) of allelic mixtures induced by CRISPR-mediated base editing events occurring at a CC sequence (green) in the EMX1 gene. The sequences of the EMX1 alleles resulting from four possible C->T base transitions (CC, CT, TC, TT) induced by CRISPR-mediated base editing and the adaptors to capture them (GG, AG, GA, AA) are shown. In these experiments HEK293T cells constitutively expressing the cytidine base editor (CBE) FNLS-BE3 were transfected with sgRNA targeting the EMX1 locus.

FIG. 4B shows the schematics of the experiments conducted to detect multiple simultaneously induced variants using DTECT. HEK293T cells constitutively expressing the base editor FNLS-BE3 were transfected with two sgRNAs to introduce simultaneously the BRCA1 E638K and the BRCA2 E2772K mutations by CRISPR-mediated base editing.

FIG. 4C shows the detection of multiple precision genome editing events introduced by CRISPR-mediated base editing in HEK293T cell populations, as illustrated in FIG. 4B. WT and edited BRCA1 and BRCA2 alleles captured using adaptors specific for the WT (TG, AG; green) or edited (TA, AA; purple) alleles were subjected to analytical (left; 21 cycles) or quantitative PCR (right).

FIGS. 5A-5J show the DTECT-mediated identification of clinically relevant BRCA1/2 mutations generated by precision genome editing and genotyping of cell lines and animal models carrying BRCA1 or BARD1 mutations.

FIG. 5A shows the schematic representation of the human BRCA1 protein. BRCA1 domains and ClinVar BRCA1 mutations generated in this study are indicated.

FIG. 5B shows the quantification using DTECT (red) and NGS (green) of the editing efficiency by which 10 BRCA1 mutations are introduced into HEK293T cells by CRISPR-mediated base editing. Experiments were conducted in cells expressing the base editor FNLS-BE3 upon transfection of sgRNAs to introduce the indicated mutations. Histograms show the mean frequency of the indicated variants estimated by DTECT and error bars represent the s.d. from 2 independent DTECT assays for the same AcuI-tagged amplicon. n.d.: not determined, due to sequencing failure.

FIG. 5C shows the analytical detection of the indicated BRCA1 mutations in HEK293T cell populations by DTECT (21 PCR cycles) using adaptors specific for WT (green) or mutant (purple) alleles.

FIG. 5D shows the schematic representation of the human BRCA2 protein. BRCA2 domains and ClinVar BRCA2 mutations generated in this study are indicated.

FIG. 5E shows the quantification using DTECT (red) and NGS (green) of the editing efficiency by which 13 BRCA2 mutations are introduced into HEK293T cells by CRISPR-mediated base editing, as described in FIG. 5B.

FIG. 5F shows the analytical detection of the indicated BRCA2 mutations in HEK293T cell populations by DTECT (21 PCR cycles) using adaptors specific for WT (green) or mutant (purple) alleles. Experiments were conducted as in FIG. 5C.

FIG. 5G shows the genotyping by DTECT-based analytical PCR (18 cycles) of single clones carrying WT and/or BRCA1 E638K mutant alleles derived from the BRCA1 E638K mutant cell population shown in FIG. 5C. WT (#4, not edited), heterozygous (#1) and homozygous (#2) BRCA1 mutant clones identified by DTECT are indicated.

FIG. 5H shows the Sanger sequencing of WT, heterozygous and homozygous mutant amplicons shown in FIG. 5G. The targeted dinucleotide is indicated in green and part of the sequence of the AcuI-tagging primer is indicated in purple.

FIG. 5I shows the genotyping by DTECT-based analytical PCR of Bard1 S563F (left) and Brca1 S1598F (right) knock-in mutant mice (Bard1, 18 PCR cycles; Brca1, 20 PCR cycles). gDNA for DTECT analysis was obtained from mouse tail samples. WT (Bard1 #8 and Brca1 #5), heterozygous (Bard1 #2 and Brca1 #2) and homozygous (Bard1 #3) mutant mice identified by DTECT are indicated. No homozygous Brca1 S1598F mutant mice were identified in the analyzed mouse litters due to sub-Mendelian birth ratios (Billing et al., 2018).

FIG. 5J shows the Sanger sequencing of WT, heterozygous and homozygous mutant amplicons shown in FIG. 5I.

FIGS. 6A-6D show the detection of oncogenic signatures in human clinical samples using DTECT.

FIG. 6A shows the schematic representation of the experiments conducted on ALL patient-derived samples. Bone marrow samples from ALL patients were collected at diagnosis and after chemotherapy. PDXs were generated from the patient samples. The genomic DNA was recovered from the patient samples and PDX mouse models and subjected to analytical and quantitative detection of NT5C2 oncogenic mutations using DTECT.

FIG. 6B provides the heat map showing the detection of NT5C2 oncogenic mutations in patient samples and a control sample using DTECT. Bone marrow samples from 5 patients were collected; genomic DNA was prepared and tested for the presence of 3 frequent NT5C2 mutations responsible for relapse to chemotherapy. A non-patient-derived gDNA sample was utilized as a control to estimate the levels of non-specific background in the DTECT assay. Data are shown as fold change in the frequency of mutant signatures in the patient samples relative to the control sample.

FIG. 6C shows the graphical representation of the frequency of NT5C2 mutations determined by DTECT (red) and NGS (green) in the 5 human patient samples analyzed in FIG. 6B. Error bars indicate the s.d. of 2 independent DTECT replicates.

FIG. 6D shows the analytical and quantitative detection of the NT5C2 R367Q mutation in PDX models generated from ALL tumors of patients #2, #4 and #5 at diagnosis and after chemotherapy relapse. WT and mutant variants were captured using adaptors specific for the WT (GA, green) or mutant (AA, purple) allele and subjected to analytical (left; 18 PCR cycles) and quantitative PCR (right).

FIG. 7 shows the DTECT applications for the detection of precision genome editing and genetic variation. It shows the schematic representation of examples of targeted dinucleotide signatures generated by single base edits, small insertions and deletions that can be detected using DTECT. Examples of adaptors that can be used to detect the indicated genome editing events are shown on the right.

FIGS. 8A-8D show the features of type IIS restriction enzymes compatible with DTECT and schematic representation of the AcuI digestion pattern.

FIG. 8A shows the representation of two key features of type IIS restriction enzymes compatible with DTECT: 1) Binding of a single recognition motif (green); 2) Cleavage of a targeted DNA sequence (blue) far from the recognition motif.

FIG. 8B shows the representation of the pattern of digestion of a type IIS enzyme, including the main digestion product and a cleavage byproduct due to slippage activity.

FIG. 8C shows the graphical representation of the number of type IIS enzymes in function of the distance between their recognition motif and cleavage site.

FIG. 8D shows the pattern of cleavage of the type IIS enzyme AcuI. AcuI cleaves DNA products 14/16 bp away from its recognition site (green), leaving a 3′-overhang of 2 DNA bases (blue).

FIGS. 9A-9C show the Sanger sequencing reads of captured AcuI-digested DNA fragments and validation of the adaptor library.

FIGS. 9A and 9B show the Sanger sequencing reads of PCR amplicons of AcuI-digested DNA products containing the TT (FIG. 9A) and CC (FIG. 9B) signatures shown in FIG. 2B, which have been captured using AA or GG adaptors. The DNA sequences of PCR primers (red), genomic locus (purple), targeted dinucleotides (blue), AcuI motif (green) and adaptors (brown) are shown.

FIG. 9C shows the PCR amplification (18 cycles) of captured AcuI-digested DNA products by DTECT using specific (green) and non-specific (blue) DNA adaptors. Each of the 16 adaptors was tested for its ability to capture two independent dinucleotide signatures (#1 and #2).

FIGS. 10A-10F show the identification of WT and STOP alleles in mixed solutions and quantification of non-specific dinucleotide capture and ligation efficiency in DTECT assays.

FIG. 10A shows the schematics of the protocol used to identify and quantify WT and STOP alleles in mixed solutions, as shown in FIGS. 2G-2I. Cells were transfected with the cytidine base editor (CBE) BE3 and an sgRNA to induce a STOP codon (sgSTOP) using iSTOP. WT and STOP alleles were then cloned and mixed at different WT:STOP ratios, as indicated in FIG. 2G. DTECT was then used to capture WT and STOP signatures using adaptors specific for the WT (green) or STOP (purple) allele, as well as non-specific adaptors (blue). Captured material was then subjected to analytical or quantitative PCR.

FIG. 10B shows the Sanger sequencing reads of WT and STOP alleles of SPRTN, SMARCAL1 and PIK3R1. The targeted dinucleotide signature is shown in green and the edited cytidine base (C->T) is indicated by the blue arrow.

FIG. 10C shows the representation of the AcuI-tagging primers used to detect the WT and STOP alleles of the SPRTN gene. The targeted dinucleotides are shown in blue, the edited base is indicated with an asterisk, the PAM sequence is show in red and part of the AcuI-tagging primer sequence is shown in purple.

FIG. 10D shows the PCR amplification (25 cycles) of WT and STOP SPRTN alleles (arrow) captured using DTECT from WT:STOP allele mixtures (i.e., 100:0 and 99:1). An adaptor (AG) specific for the STOP SPRTN allele is utilized in the capture reaction, along with an adaptor specific for the WT allele (GG; positive control) and a non-specific adaptor (TT; negative control). Background non-specific PCR products are indicated with an asterisk.

FIG. 10E shows the frequency of non-specific dinucleotide capture for each of the 16 adaptors used for DTECT. Adaptors containing the indicated dinucleotide sequences were utilized to capture AcuI-digested DNA fragments with non-complementary dinucleotides and the frequency of non-specific dinucleotide capture was quantified by qPCR. Mean frequency of non-specific dinucleotide capture is shown for 2-6 independent DNA ligation reactions using DNA fragments with distinct non-complementary dinucleotides. Adaptors complementary to +1 and −1 AcuI-dependent slippage events were excluded from the analysis.

FIG. 10F shows the time course experiment to measure the efficiency of the ligation of AcuI-digested products to DNA adaptors. AcuI-digested products from 3 independent targets (SMARCAL1, SPRTN and PIK3R1), DNA adaptors and T4 ligase were incubated for 5 min, 1 hour or 16 hours, and the captured material was quantified by qPCR. A sample without T4 ligase was used as a negative control. The percentage of captured material at the different time points was obtained by normalization to the amount of captured material upon a 16-hour ligation reaction. Error-bars represent the s.d. of 2 independent experiments.

FIGS. 11A-11J show the detection of CRISPR-mediated HDR and base editing events by DTECT, NGS and RFLP assays.

FIGS. 11A-11D show the detection by analytical PCR (20 or 21 cycles) of WT and HDR-edited EMX1 (FIG. 11A), JAK2 (FIG. 11B), HBB (FIG. 11C) and BRCA2 (FIG. 11D) alleles captured using adaptors specific for the WT (green) or edited (purple) alleles. In these experiments HEK293T cells were transfected with Cas9, sgRNA and an HDR donor (ssODN) with or without the HDR stimulatory factor i53. The ssODN was omitted in control reactions. ssODNs introduce a Pmel site in EMX1 and JAK2, a sickle cell anemia mutation in HBB (i.e., G6V), and a breast cancer-associated small tandem duplication in BRCA2 (dupAGAAGAT).

FIG. 11E shows the quantification of the efficiency of the insertion of the short tandem duplication dupAGAAGAT in the BRCA2 locus, as determined by NGS. The pie chart shows the distribution of NGS reads corresponding to HDR- and/or NHEJ-mediated repair events (HDR, red; NHEJ, blue; mixed HDR/NHEJ, green; unedited, brown) occurring at the BRCA2 locus in HEK293T cells transfected with Cas9/sgRNA and ssODN donor, with or without i53. In these experiments, the BRCA2 locus was amplified by PCR and subjected to NGS. The NGS reads were analyzed by CRISPResso.

FIG. 11F shows the RFLP assay to monitor the gain of a Pmel restriction site introduced by ssODN-meditated HDR in the EMX1 and JAK2 loci under the same experimental conditions shown in FIG. 11A and FIG. 11B. Digested (edited) and undigested (WT) DNA products are indicated by arrows.

FIGS. 11G-11H show the RFLP assays to monitor the loss of Ncol (FIG. 11G) or Taqal (FIG. 11H) restriction sites in the HBB and TP53 loci, respectively, resulting from the insertion of the G6V and R209fs*6 mutations under the same experimental conditions shown in FIG. 11C and FIG. 3B. Digested (WT) and undigested (edited) DNA products are indicated by arrows.

FIG. 11I shows the detection of WT and nonsense mutant TIMELESS, SLX4 and FANCM alleles by DTECT using adaptors specific for the WT (green) or edited (purple) signatures. Experiments were performed in cells transfected with the cytidine base editor BE3 and sgRNA to induce the indicated nonsense mutations, which were detected by analytical (left; 21 cycles) or quantitative PCR (right).

FIG. 11J shows the detection of WT and nonsense mutant TCOF1 alleles by DTECT (21 PCR cycles) using adaptors specific for the WT (GG, green) or edited (AG, purple) allele. Experiments were performed in cells transfected with BE3 and sgRNA to induce the indicated nonsense mutation in the TCOF1 gene. The introduction of the nonsense mutation was confirmed by Sanger sequencing (bottom) and by an RFLP assay that monitors the loss of an XcmI restriction site at the edited locus (right).

FIGS. 12A-12B show the comparative analysis of DTECT-, Sanger- and NGS-based estimations of the frequency of genetic variants generated by precision genome editing.

FIG. 12A shows the graphical representation of the frequency of mutations introduced by CRISPR-dependent HDR and base editing in human and mouse cells, and intestinal organoids. The FANCF, Pik3ca and Apc loci were edited in biological duplicate or triplicate using multiple base editors, and the resulting edited samples were previously described (Zafra et al., 2018). The BRCA1/2 loci were edited using BE3. The frequency values were determined by both DTECT (red) and NGS (green). NGS was conducted on standard PCR amplicons (FANCF, Pik3ca and Apc) or AcuI-tagged amplicons (BRCA1/2) of the edited loci. Error bars represent the s.e.m. of 2-5 independent DTECT assays per edited sample. The same frequency values are plotted in the graphs shown in FIG. 3C.

FIG. 12B shows the graphical representation of the correlation between technical duplicates obtained by DTECT (red), EditR (green) or ICE (blue). Each dot represents a distinct BRCA1/2 variant introduced in cells by precision genome editing. Technical duplicates of DTECT assays correspond to two independent ligation reactions for the same AcuI-digested amplicon and Sanger-based technical duplicates correspond to two independent sequencing reactions for the same PCR amplicon.

FIGS. 13A-13C show the detection of base editing byproducts and clinically relevant BRCA1/2 mutations introduced by precision genome editing.

FIG. 13A shows the detection by analytical PCR (21 cycles) of allelic mixtures induced by CRISPR-mediated base editing events occurring at a CC sequence in the EMX1 gene, as shown in FIG. 4A. In these experiments HEK293T cells constitutively expressing the base editor FNLS-BE3 were transfected with a control sgRNA (top) or an sgRNA targeting the EMX1 locus (bottom). All possible 16 adaptors were used to capture EMX1 variants. Adaptors that capture the WT allele (GG) and +1 AcuI slippage event (CG) are shown in green and orange. Adaptors that capture C->T base editing events (AA, AG, GA) and C->A and C->G base editing byproducts (AC, AT, CA, CG, GC) are also shown.

FIGS. 13B-13C show the analytical detection of the indicated BRCA1 (FIG. 13A) and BRCA2 (FIG. 13B) mutations in HEK293T cell populations by DTECT (21 PCR cycles) using adaptors specific for WT (green) or mutant (purple) alleles. Experiments were conducted as in FIGS. 5C and 5F.

FIGS. 14A-14B show the genotyping of mutant cellular clones and knock-in mice using DTECT.

FIG. 14A shows the genotyping by DTECT-based analytical PCR (20 cycles) of HEK293T clones (17) carrying WT and/or BRCA1 E638K mutant alleles or base editing byproducts derived by single cell dilution from the BRCA1 E638K cell population shown in FIG. 5C. Heterozygous and homozygous mutant clones are indicated in blue and purple, respectively. WT clones are indicated in green and a clone with a base editing byproduct is indicated in orange. Clones #1, #2, #4 and control (CTL) are also shown in FIG. 5G. Quantification of each BRCA1 variant by qPCR is also shown (bottom). HEK293T cells have 4 BRCA1 alleles. Error bars correspond to two independent experiments.

FIG. 14B shows the genotyping by DTECT-based analytical PCR of Bard1 S563F (top) and Brca1 S1598F (bottom) knock-in mutant mice (Bard1, 18 PCR cycles; Brca1, 20 PCR cycles). DTECT assays were conducted on gDNA isolated from mouse tail samples. Heterozygous and homozygous mutant mice are indicated in blue and purple, respectively, and WT mice are indicated in green. No homozygous Brca1 S1598F mutant mice were identified in the analyzed mouse litters due to sub-Mendelian birth ratios (Billing et al., 2018). Mice #1, #2, #3 and #8 (Bard1), and #1, #2, #5 (Brca1) are also shown in FIG. 5I.

FIGS. 15A-15D show the detection of oncogenic mutations in a mouse model of myeloproliferative neoplasm and in ALL patients using DTECT.

FIG. 15A shows the schematics of the experiments conducted to detect the Jak2 V617F mutation in a mouse model of myeloproliferative neoplasm. Peripheral blood was collected from mice transplanted with a mixture of bone marrow cells either wild-type (WT) or carrying an inducible Jak2 V617F mutant allele (Mx1-Cre⁺; Jak2^(V617F/+)). DTECT was then utilized to determine the presence of the Jak2 V617F mutation in gDNA extracted from the collected blood samples.

FIG. 15B shows the schematic representation of 4 AcuI-induced dinucleotide signatures that enable the identification of Jak2 WT and V617F alleles. The G in red is replaced by a T in the Jak2 V617F mutant allele.

FIG. 15C shows the identification by DTECT-based analytical PCR (20 cycles) of the Jak2 V617F mutation in the blood of a mouse model of myeloproliferative neoplasm generated as described in FIG. 15A. The Jak2 V617F mutation was identified using the 4 independent dinucleotide signatures shown in FIG. 15B. gDNA samples from peripheral blood of WT mice were used as controls (#1 and #2) in this experiment. Sanger sequencing (bottom) was conducted to confirm the results obtained using DTECT.

FIG. 15D shows the analytical detection of the indicated NT5C2 mutations in ALL patient samples by PCR (20 cycles). The frequency of the indicated mutations in the same patient samples is shown in FIG. 6B.

FIGS. 16A-16C show the analysis of ClinVar variants with proximal genomic AcuI motifs compatible with DTECT.

FIG. 16A shows the Bioinformatic analysis of ClinVar database variants (425,580) with (80,326; blue) or without (345,254; green) genomic AcuI sites in close proximity (+/−100 bp). Variants (green, right pie chart) with a single AcuI motif located 35 bp to 100 bp away on the 3′-(29,848) or 5′-(29,291) side can be detected using DTECT, as illustrated in FIG. 16C. Variants (red, right pie chart) with an AcuI motif located <35 bp away (18,739) or with proximal AcuI motifs on both sides (2,448) cannot be detected using DTECT.

FIG. 16B shows the percentage and number of ClinVar variants that can (95.02%, 404,393) or cannot (4.98%, 21,187) be detected using DTECT.

FIG. 16C shows the schematic representation of genomic loci with or without an AcuI site in close proximity to the edited site. When a genomic AcuI site is located 35 bp to 100 bp away from the edited site, detection of the edited site can be obtained by designing 2 AcuI-tagging primers that anneal to the targeted locus between the genomic AcuI site and the edited base(s). This approach allows the capture of two independent dinucleotide signatures for each targeted site with one proximal AcuI site. Four independent dinucleotide signatures can be captured for targeted sites with no proximal AcuI sites.

FIGS. 17A-17B show the detection of AcuI slippage events by DTECT.

FIG. 17A shows the schematics of targeted dinucleotides (blue) and +1 (red) and −1 (orange) AcuI slippage events (left). Detection of AcuI slippage byproducts by DTECT (22 PCR cycles) using adaptors complementary to the targeted dinucleotide signatures (green) and to signatures generated by AcuI+1 (red) or −1 (orange) slippage (right). A non-specific adaptor (blue) is used as a control.

FIG. 17B shows the schematic representation of DNA digestion products generated by precise AcuI cleavage (green) or +1 slippage (red) occurring at wild-type and mutant alleles. The dinucleotide signatures generated as a result of AcuI slippage byproducts and the complementary adaptors to capture them are indicated.

FIGS. 18A-18D show the design of DTECT assays to avoid indel interference in CRISPR-mediated HDR experiments.

FIG. 18A shows the InDelphi prediction (https://indelphi.giffordlab.mit.edu) of indel-containing alleles in the TP53 locus. The dinucleotides targeted to simultaneously introduce the TP53 R209fs*6 mutation and a G->T mutation in the PAM by CRISPR-dependent HDR are indicated in green and red, respectively. The Cas9 cleavage site is indicated in black. The dinucleotide signatures captured to detect the TP53 R209fs*6 and PAM mutations are shown in purple. The presence of indel interference in the distinct predicted alleles is indicated. MH, microhomology.

FIG. 18B shows the DTECT-based quantification of the TP53 R209fs*6 and PAM mutations introduced by HDR using a single ssODN donor template, as shown in FIG. 18A. Adaptors specific for the WT (CT and TG; green and red) or edited (TT; purple) signatures were used for quantification. HDR efficiency determined by NGS is also shown.

FIG. 18C shows the schematic representation of the design of DTECT experiments to avoid interference of indels formed at DSBs during CRISPR-mediated HDR. Cas9-mediated DSBs are induced at a distance from a targeted dinucleotide (green) sufficient to avoid mutation of the targeted dinucleotide by indels (blue). The pattern of indel mutations is predicted using the InDelphi website.

FIG. 18D shows the schematics of alleles generated by CRISPR-mediated HDR, including the unedited allele (green), indel-containing alleles (blue) and the HDR-edited allele (purple). Using the experimental design shown in FIG. 18C, DTECT captures both the unedited and the indel-containing alleles using an adaptor specific for the WT dinucleotide signature, while the HDR-edited allele is captured using an adaptor specific for the edited dinucleotide signature. The capture of indel-containing alleles with a WT adaptor ensures the accurate quantification of the frequency of the HDR-edited allele in the allele population.

DETAILED DESCRIPTION OF THE DISCLOSURE

The present disclosure provides a versatile method that uses standard molecular biology techniques to detect variants introduced by precision genome editing or resulting from genetic variation. This detection method, designated Dinucleotide signaTurE CapTure (DTECT), enables accurate and sensitive quantification of marker-free precision genome editing events induced by CRISPR-dependent HDR, base editing and prime editing. In addition, we show that DTECT can readily identify oncogenic mutations in cancer mouse models, patient-derived xenograft models and cancer patient samples. These studies establish a cost-effective method for the rapid detection of genetic variants, which will aid the generation of marker-free cellular and animal models of human disease and expedite the detection of pathogenic variants for clinical applications.

Accordingly, one embodiment of the present disclosure is a DNA adaptor comprising: (a) one strand with sequence of 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCTTCTAAGAATTCGAGCTCGGTACC CG-3′ (SEQ ID NO: 230); and (b) one complementary strand with sequence of 5′-CGGGTACCGAGCTCGAATTCTTAGAAGAGAGACAGAATGCTTCTTACCCGTGCCC CAGNN-3′ with “N” corresponding to A, T, G or C (SEQ ID NOs: 231-246).

In some embodiments, the DNA adaptor is labeled with a detection molecule. Non-limiting examples of the detection molecule include a radiolabel, a fluorescent label, a biotinylated label, a non-fluorescent label, an enzyme, a hapten, a phosphorescent molecule, a chemiluminescent molecule, a chromophore, a luminescent molecule, a photoaffinity molecule, a color particle or a ligand.

Another embodiment of the present disclosure is a method of preparing a DNA adaptor disclosed herein, comprising: (a) synthesizing one constant oligonucleotide with sequence of 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCTTCTAAGAATTCGAGCTCGGTACC CG-3′ (SEQ ID NO: 230); (b) synthesizing one complementary oligonucleotide with sequence of 5′-CGGGTACCGAGCTCGAATTCTTAGAAGAGAGACAGAATGCTTCTTACCCGTGCCC CAGNN-3′ with “N” corresponding to A, T, G or C (SEQ ID NOs: 231-246); (c) mixing the constant and complementary oligonucleotides; and (d) annealing the mixture to obtain the DNA adaptor.

Another embodiment of the present disclosure is a library of DNA adaptors prepared by methods disclosed herein, the library comprises 16 DNA adaptors, wherein each DNA adaptor has a different “NN”.

Another embodiment of the present disclosure is a method for detecting a genetic modification, comprising the steps of: (a) amplifying a genomic locus of interest using a specially designed Type IIS restriction enzyme-tagging primer, comprising: (i) extracting genomic DNA from a biological sample of interest; (ii) synthesizing the Type IIS restriction enzyme-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the Type IIS restriction enzyme-tagging primer and a reverse primer; and (iv) purifying a Type IIS restriction enzyme-tagged genomic amplicon; (b) digesting the Type IIS restriction enzyme-tagged genomic amplicon with the Type IIS restriction enzyme; (c) isolating the smaller DNA fragment containing a genomic signature of interest exposed in a 3′ single-stranded overhang; (d) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment containing the 3′ overhang signature with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (e) amplifying the ligated product to detect the presence of the genetic modification.

In some embodiments, the genetic modification is selected from a base change, a deletion, or an insertion. In some embodiments, the genetic modification is selected from a single genomic change or multiple genomic changes. In some embodiments, the multiple genomic changes can occur within a single locus or distinct loci.

In some embodiments, the Type IIS restriction enzyme is selected from AcuI, BpmI, BpuEI, BsgI, MmeI and NmeAIII. In some embodiments, the Type IIS restriction enzyme is selected from AcuI and BpuEI. In some embodiments, the Type IIS restriction enzyme is AcuI.

In some embodiments, the Type IIS restriction enzyme-tagging primer is an oligonucleotide comprising: (a) a non-complementary handle sequence positioned on the 5′ side; (b) a complementary sequence of the genomic locus of interest on the 5′ side; (c) a recognition motif of the Type IIS restriction enzyme that is positioned at a predicted distance from its cleavage site to generate the genomic signature of interest; and (d) a complementary sequence of the genomic locus of interest on the 3′ side.

In some embodiments, the reverse primer is positioned at more than 100 bp downstream of the genomic locus of interest.

In some embodiments, the non-complementary handle sequence can have any suitable length. In some embodiments, the non-complementary handle sequence is 25 bp. In some embodiments, the non-complementary handle sequence can have any suitable sequence. In some embodiments, the non-complementary handle sequence is 5′-GCAATTCCTCACGAGACCCGTCCTG-3′ (SEQ ID NO: 3).

In some embodiments, the ligation in step (d)(ii) of the methods disclosed above is carried out by T4 DNA ligase.

A further embodiment of the present disclosure is a kit for detecting a genetic modification of interest, comprising a specially designed Type IIS restriction enzyme-tagging primer disclosed herein, and a library of DNA adaptors disclosed herein, packaged together with instructions for its use. In some embodiments, the Type IIS restriction enzyme is AcuI.

Another embodiment of the present disclosure is a method for detecting a genetic modification, comprising the steps of: (a) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (b) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (c) isolating the smaller DNA fragment containing a genomic signature of interest produced by AcuI-digestion; (d) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (e) amplifying the ligated product to detect the presence of the genetic modification.

In some embodiments, the AcuI-tagging primer is an oligonucleotide comprising: (a) a non-complementary handle sequence positioned on the 5′ side; and (b) a complementary sequence of the genomic locus of interest containing an AcuI motif (5′-CTGAAG-3′) positioned 14 bp upstream from the genomic locus of interest.

In some embodiments, the AcuI-tagging primer can have any suitable length. In some embodiments, the AcuI-tagging primer is 60 bp.

In some embodiments, the reverse primer is positioned at more than 100 bp downstream of the genomic locus of interest.

In some embodiments, the non-complementary handle sequence can have any suitable length. In some embodiments, the non-complementary handle sequence is 25 bp.

In some embodiments, the complementary sequence has the structure of: 5′-N(20)CTGAAGN(14)-3′ or 5′-N(15)CTGAAGN(14)-3′, with “N” corresponding to A, T, G or C, depending on the DNA sequence of the genomic locus of interest.

In some embodiments, the non-complementary handle sequence is 5′-GCAATTCCTCACGAGACCCGTCCTG-3′ (SEQ ID NO: 3) and the complementary sequence is 5′-N(15)CTGAAGN(14)-3′, with “N” corresponding to A, T, G or C.

In some embodiments, the ligation in step (d)(ii) of the methods disclosed above is carried out by T4 DNA ligase.

An additional embodiment of the present disclosure is a kit for detecting a genetic modification, comprising a specially designed AcuI-tagging primer and a library of DNA adaptors disclosed herein, packaged together with instructions for its use.

Another embodiment of the present disclosure is a method for quantifying a genomic variant in a biological system, comprising the steps of: (a) obtaining a sample from the biological system; (b) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (c) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing a genomic signature of interest produced by the AcuI-digestion; (e) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (f) quantifying the genomic variant and determining its relative abundance.

In some embodiments, the genomic variant is generated by precision genome editing. In some embodiments, the precision genome editing is CRISPER-dependent homology-directed repair, base editing or prime editing.

In some embodiments, the biological system is a mammalian cell line, an organoid, or a tissue.

In some embodiments, the quantification in step (f) of the methods disclosed above is carried out by quantitative PCR (qPCR).

Still another embodiment of the present disclosure is a method for identifying and quantifying an oncogenic mutation of interest in a biological sample, comprising the steps of: (a) obtaining a biological sample; (b) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (c) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing a genomic signature of interest produced by the AcuI-digestion; (e) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors disclosed herein; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; (f) amplifying the ligated product to identify the presence of the oncogenic mutation of interest; and (g) quantifying the oncogenic mutation of interest, if present, and determining its frequency.

In some embodiments, the biological sample is obtained from a cancer animal model, a patient-derived xenograft (PDX), or a human cancer patient sample.

In some embodiments, the quantification in step (g) of the methods disclosed above is carried out by quantitative PCR (qPCR).

A further embodiment of the present disclosure is a process for marker-free detection of a precision genome editing event comprising carrying out Dinucleotide signaTurE CapTure (DTECT) on a nucleic acid sequence of interest.

DTECT can also be used to detect genetic signatures in any organism, for example, a virus. Thus, still another embodiment of the present disclosure is a method for detecting a virus variant of interest, comprising the steps of: (a) obtaining a nucleic acid of the virus variant of interest from a biological sample; and (b) if the nucleic acid is DNA, carrying out Dinucleotide signaTurE CapTure (DTECT) to detect the variant of interest; or (c) if the nucleic acid is RNA, coverting it to DNA by reverse transcription PCR (RT-PCR) and then carrying out DTECT to detect the variant of interest. This detection method is applicable to any type of virus including but not limited to a DNA virus, an RNA virus, a retrovirus, etc. In some embodiments, the virus is an RNA virus. In some embodiments, the virus is SARS-CoV-2.

The following examples are provided to further illustrate the methods of the present disclosure. These examples are illustrative only and are not intended to limit the scope of the disclosure in any way.

EXAMPLES Example 1 Methods and Materials

Material Availability

Plasmids for DTECT quantification and expression of base editing sgRNAs targeting BRCA1, BRCA2 and FANCD2 have been deposited to Addgene (#139321-139333, and 139511).

Cell Line Generation and Single Clone Isolation

HEK293T and DLD1 cell lines were obtained from ATCC. Cells were cultured in DMEM (ThermoFisher Scientific) supplemented with 10% Fetalgro bovine growth serum (BGS, RMBIO) and 1% penicillin-streptomycin (ThermoFisher Scientific). Cells were grown at 37° C. with 5% CO₂ and tested regularly for mycoplasma. NIH/3T3 were maintained in DMEM supplemented with 10% bovine calf serum. Organoids were isolated and cultured as previously described (Zafra et al., 2018). To generate cells constitutively expressing FNLS-BE3-P2A-BlastR, HEK293T cells were infected with a lentivirus expressing the above construct. Viruses were produced in HEK293T in 6-well plates by transfecting 2 μg of FNLS-BE3-P2A-BlastR, 0.2 μg of Tat, 0.2 μg of Gag/Pol, 0.2 μg of Rev, 0.4 μg of VSV-G expressing plasm ids in 250 μl of DMEM without serum. 9 μl of TranslT-293 (Mirus) were added to the DNA, mixed and incubated for 15 min at room temperature. The DNA transfection reagent mix was added dropwise to the cells and incubated at 37° C. with 5% CO₂. The next day the cell medium was replaced and cells were incubated for 48 hours. The medium containing lentiviruses was then collected and utilized to infect new HEK293T cells. 48 hours after infection, blasticidin was added to the medium until the uninfected control cells were killed. FNLS-BE3 expression was determined by western blot and the base editing activity of the construct was tested using previously validated sgRNAs. Single HEK293T clones were selected for high base editing efficiency. Clones were isolated by trypsinization of the initial cell population into individual cells. Cell density was evaluated by counting the cells with a hemocytometer and cells were diluted to approximately 0.13 cells/μl, equivalent to 20 cells per 150 μl. Serial dilutions were prepared and 150 μl of the diluted cell mixture were seeded into 96-well plates. Single clones were expanded and further examined for FNLS-BE3 expression and activity.

Editing of Cell Lines, Organoids and Mice

To induce CRISPR-mediated HDR editing, HEK293T cells were seeded at 50%-70% confluency into 24-well plates and reverse transfected with 0.25 μg of sgRNA and 0.25 μg of Cas9 expressing plasmid (Addgene #42230) with or without 0.5 μl of ssODN (40 μM) into 100 μl of DMEM without Fetalgro BGS and antibiotics. 3 μl of TranslT-293 (Mirus) were added to the DNA, mixed and incubated for 15 min at room temperature. Experiments involving i53 were done by adding 0.25 μg of i53 (Addgene #77939) to the transfection mixture. The gDNAs of cell populations and individual clones were recovered by resuspending the cell pellets in the Quick Extract DNA Extraction Solution (Epicentre), followed by incubation at 65° C. for 10 min and 95° C. for 5 min. The isolated gDNAs were diluted in H₂O, quantified using Nanodrop and stored at −20° C. or directly used in PCR reactions. In base editing experiments, we used cells constitutively expressing FNLS-BE3 or transfected with pCMV-BE3 (Addgene #73021) and sgRNAs, as described above. Empty plasmids (Addgene #100708) with no sgRNAs were used as controls. To determine the accuracy of the quantification of variant frequency by DTECT (FIG. 2G), STOP codons were introduced into SPRTN, SMARCAL1 and PIK3R1 genes using iSTOP, as previously described (Billon et al., 2017). To isolate the WT alleles, the locus was amplified by PCR and cloned into the pCR-Blunt II-TOPO vector (ThermoFisher Scientific). The STOP alleles were isolated by PCR amplification using gDNA that was partially edited as template. The PCR product was subsequently digested using restriction enzymes that specifically cleave the WT PCR alleles (i.e., Pvull for SPRTN, SfaNI for SMARCAL1 and Taqal for PIK3R1). The digestion reaction was loaded on a 2% agarose gel and the undigested PCR products were column purified (Zymoclean #D4008). The purified products were subsequently cloned into the pCR-Blunt II-TOPO vector (ThermoFisher Scientific). Cloned WT and STOP PCR fragments were confirmed by Sanger sequencing and are shown in FIG. 10B. RFLP assays were conducted by digesting PCR amplicons of the edited genomic loci with enzymes that recognize restriction sites created or disrupted by editing of the targeted loci. Restriction digest products were run on 6% TBE polyacrylamide gels. Gels were run at 160 V in 1×TBE and stained for 5 min using SybrGold diluted in 1×TBE buffer. In prime editing experiments, 1 μg of pCMV-PE2 (Addgene #132775) was transfected into HEK293T cells along with 500 ng of control pegRNA (Addgene #132777) or pegRNA HEK3 insCTT (Addgene #132778). Three days after transfection, genomic DNA was recovered as above and the edited signature was identified with DTECT. Edited DLD1 (FANCF locus) and NIH/3T3 (Pik3ca and Apc loci) cell populations and mouse intestinal organoids (Pik3ca and Apc loci) were previously described (Zafra et al., 2018). Genomic DNA from the edited cell populations was used to quantify the editing efficiency by DTECT (FIG. 12A).

In order to introduce multiple variants into the BRCA1 and BRCA2 genes, HEK293T cells expressing FNLS-BE3 were seeded at 50%-70% confluency into 24-well plates and reverse transfected with 1 μg of sgRNA into 100 μl of DMEM without Fetalgro BGS and antibiotics. 3 μl of TranslT-293 (Mirus) were added to the DNA, mixed and incubated for 15 min at room temperature. The DNA transfection mix was added dropwise to the cells and incubated at 37° C. with 5% CO₂ for 4 days. Single clones were generated and the gDNAs of cell populations and individual clones were recovered as describe above. Genomic loci were Sanger sequenced by Eton Bioscience or Genewiz. Sanger sequencing data were analyzed using Serial cloner and viewed by Snapgene Viewer. The sequencing profiles shown in this manuscript were generated by SnapGene Viewer. Quantitative detection of the editing level using the AcuI-tagged amplicon was done blindly.

In vivo mouse editing was performed as previously described (Zafra et al., 2018). Briefly, eight week-old C57BL/6N mice (Charles River) were injected with 0.9% sterile sodium chloride solution containing 20 μg of pLenti-FNLS-P2A-Puro and 10 μg of sgRNA vector. The total injection volume corresponded to 20% of the individual mouse body weight and was injected into the lateral tail vein in 5-7 seconds. All animal experiments were authorized by the regional board of Karlsruhe, Germany.

Mouse Genotyping and Bone Marrow Transplantation

The generation of genetically engineered mice harboring the Brca1 S1598F and Bard1 S563F alleles was previously described (Billing et al., 2018; Shakya et al., 2011). Mouse genotyping was performed using DTECT on genomic DNA extracted from mouse tails. AcuI-tagging of the targeted loci was performed using 50 ng of gDNA (see DTECT protocol above). All primer sequences are listed in Table S1. Genotyping experiments were conducted blindly.

Competitive transplantation experiments were performed to assess chimerism of Jak2 V617F mutant cells in relation to wild-type support. Specifically, Mx1-Cre⁺; CD45.2 Jak2^(V617F/+) and Mx1Cre⁺; CD45.1 wild-type mice were dosed with polyinosine-polycytosine (PIPC) 8 weeks prior to sacrifice to induce MPN in mutant mice. On day of sacrifice, dissected femurs and tibias were isolated and bone marrow flushed with a syringe into PBS. Red blood cells (RBCs) were lysed in ammonium chloride-potassium bicarbonate lysis buffer for 10 min on ice. 1.5×10⁶ filtered whole donor Mx1-Cre⁺; Jak^(2V617F/+) bone marrow cells (CD45.2) were then mixed with wild-type 1.5×10⁶ competitor bone marrow cells (CD45.1) and transplanted via tail vein injection into lethally irradiated (2×550 Rad) CD45.1 host mice. Mice were then monitored serially for the development of MPN based on blood counts and donor chimerism by retroorbital bleed draws using heparinized microhematocrit capillary tubes (ThermoFisher Scientific). After 3 consecutive hematocrits of >65%, mice were then sacrificed for peripheral blood fluorescence-activated cell sorting (FACS) analysis and DNA extraction. All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees at Memorial Sloan Kettering Cancer Center. The conditional Mx1-Cre⁺; Jak^(2V617F/+) mice are all C57BL/6 background and have been previously described (Mullally et al., 2010). Automated peripheral blood counts were obtained using a ProCyte Dx (IDEXX Laboratories) according to the manufacturer's protocol. For surface flow cytometry of mouse peripheral blood, bone marrow, and spleen, RBCs were lysed and stained with monoclonal antibodies in PBS plus 1% BSA for 1 hour on ice. For flow cytometry of erythroid lineage, bone marrow or splenic cells were stained without RBC lysis. DAPI was used for live/dead cell analysis. Cell populations were analyzed using an LSR Fortessa (Becton Dickinson), and data were analyzed with FlowJo software (Tree Star). DNA extraction was performed using the QIAamp DNA Micro Kit (Qiagen) per manufacturer's protocol.

Analysis of ALL Patient Samples and PDXs

DNA samples from leukemic ALL blasts obtained at diagnosis and after relapse were provided by multiple institutions, as previously described (Oshima et al., 2016). Informed consent was obtained at study entry and samples were collected under the supervision of local Institutional Review Boards for participating institutions and analyzed under the supervision of the Columbia University Irving Medical Center Institutional Review Board. Research was conducted in compliance with ethical regulations. ALL patients received standard combination chemotherapy at diagnosis. Diagnosis and relapse samples were harvested from bone marrow. High molecular weight genomic DNA from matched diagnosis and relapse samples of ALL patients was extracted from patient leukemic blasts or from xenografts using the DNeasy Blood & Tissue Kit (Qiagen) or the AllPrep DNA/RNA Mini Kit (Qiagen). Primary human xenograft ALL cells were passaged and harvested from the spleens of NRG (NOD.Cg-ag1tm1MomII2rgtm1WjI/SzJ, The Jackson Laboratory) mice. Whole exome sequencing was performed and analyzed as previously described (Oshima et al., 2016).

Vector Construction and Cloning

sgRNAs were synthesized as complementary oligonucleotides (IDT) compatible with BbsI restriction sites located into the B52 plasmid (Addgene #100708). Oligonucleotides were designed as previously described (Billon et al., 2017). Cloned sgRNAs were verified by Sanger sequencing. Sequences of the sgRNAs are available in Table S1. ssODNs used in HDR experiments were synthesized as ultramer oligos (IDT) and their sequences are available in Table S1. To generate the FNLS-BE3-P2A-BlastR plasmid, the pLenti-FNLS-P2A-Puro plasmid (Addgene #110841) (Zafra et al., 2018) was modified by replacing the puromycin resistance gene with the blasticidin resistance gene. Briefly, the blasticidin resistance gene coding sequence was amplified by PCR and recombined using Gibson assembly into FNLS-BE3-P2A. The FNLS-BE3-P2A-BlastR sequence was verified by Sanger sequencing.

AcuI-Tagging Primer Design

The AcuI-tagging oligonucleotide enables the insertion of an AcuI motif (5′-CTGAAG-3′) 14 bp away from a targeted dinucleotide. This motif is inserted as a hairpin in the middle of a sequence complementary to the targeted genomic locus. The AcuI-tagging oligonucleotide is 60 bp-long and contains a non-complementary handle sequence of 20-25 bp. Common handle sequences used are PB547 (5′-GATCCTCTAGAGTCGACCTG-3′) (SEQ ID NO: 1) or PB1072 (5′-GCAATTCCTCACGAGACCCGTCCTG-3′) (SEQ ID NO: 3) (Table S1). The oligonucleotide sequence complementary to the targeted genomic locus plus the AcuI motif has the following sequence: 5′-N(20)CTGAAGN(14)-3′ or 5′-N(15)CTGAAGN(14)-3′, with “N” corresponding to A, T, G or C bases complementary to the targeted locus. Reverse primers used in AcuI-tagging reactions were designed by Primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/) using the default parameters with the following changes: Mispriming library=“HUMAN” for amplifying from human genomic DNA or Mispriming library=“RODENT” for amplifying from mouse genomic DNA, Primer size “min=25, Opt=27, Max=30”, Primer Tm “Min=57.0° C., Opt=60.0° C., Max=63.0° C.”. Reverse primers are located >100 bp away from the targeted dinucleotides. All sequences of the primers used in this study are available in Table S1.

Adaptor Library Generation and Characterization

A set of 17 individual oligonucleotides constitutes the full adaptor library. This library contains: a) One constant oligonucleotide with the following sequence: 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTcttctaagaattcgagctcggtacccg-3′ (SEQ ID NO: 230). The lowercase nucleotide sequence located at the 3′-end of the constant oligonucleotide (5′-cttctaagaattcgagctcggtacccg-3′) (SEQ ID NO: 319) corresponds to the handle sequence used to detect the ligated products with either PB548 (5′-cgggtaccgagctcgaattc-3′) (SEQ ID NO: 2) or PB1073 (5′-cgggtaccgagctcgaattcttagaag-3′) (SEQ ID NO: 4); b) 16 variable oligonucleotides that contain a sequence complementary to the constant oligonucleotide plus one of 16 different dinucleotides at their 3′-end. The variable oligonucleotides have the following sequence: 5′-cgggtaccgagctcgaattcttagaagAGAGACAGAATGCTTCTTACCCGTGCCCCAGNN-3′. NN, with N=A, C, G or T (SEQ ID NOs: 231-246), corresponds to the dinucleotide that is different for each of the 16 oligos. The adaptor sequences are available in Table S1. The constant oligonucleotide and each variable oligonucleotide were resuspended at a concentration of 100 μM in H₂O. 2.5 μl of constant oligonucleotide and 2.5 μl of each variable oligonucleotide were mixed with 1× ligase buffer (ThermoFisher Scientific) and water in a 20 μl reaction. The reactions were placed in a thermocycler and oligonucleotides were annealed by incubating them for 5 min at 95° C., followed by a gradual temperature decrease from 95° C. to 15° C. After annealing was completed, 100 μl of water were added to dilute the adaptors in a 120 μl final volume. Adaptors were frozen and stored at −20° C.

The adaptor library was tested at two independent loci, as shown in FIG. 9C. In this assay, AcuI-tagging oligonucleotides targeting the ampicillin resistance gene were designed following the rules detailed above (Table S1). First, we linearized the pUC19 plasmid as follows: 1.5 μg of pUC19, 1× CutSmart Buffer (NEB) and 0.75 μl of BamHI-HF were mixed in a 30 μl reaction and incubated for 2 hours at 37° C. The digested plasmid was subsequently purified on column (Zymoclean #D4008) and used as a template in PCR reactions with each AcuI-tagging primer and a constant reverse primer (5′-CCAATGCTTAATCAGTGAGG-3′) (SEQ ID NO: 320) located at the 3′-side of the ampicillin resistance gene. The PCRs were performed in a 25 μl reaction containing: 1 μM forward and reverse primers, 0.1 mM dNTP (NEB #N0447L), 1×Q5 buffer (NEB), 20 ng of digested pUC19, 1 unit of Q5 polymerase (NEB) and water. The PCR program used was the following: 95° C. for 1 min, 40 cycles of 95° C. for 10 s, 58° C. for 10 s, 72° C. for 45 s and a final amplification step of 1 min at 72° C. PCR reactions were loaded on a 2% agarose gel, extracted from gel and purified on column (Zymoclean #D4008). Finally, the DTECT protocol was applied as described below. Briefly, 0.5 pmol of AcuI-tagging PCR products were digested by AcuI for 30 min at 37° C. 10 μl of the digested products were purified with 18 μl of solid phase reversible immobilization magnetic beads (Beckman Coulter #A63881). 20 μl of supernatant (unbound fraction) were recovered and 0.5 μl of this supernatant were ligated using complementary and negative control adaptors for 1 hour at 25° C., followed by T4 ligase inactivation for 10 min at 65° C. The complementary and negative control adaptors used in FIG. 9C are the following: AA #1 (Specific adaptor: TT, Non-specific adaptor: CC), AA #2 (TT, CC), AC #1 (GT, AC), AC #2 (GT, AA), AG #1 (CT, GA), AG #2 (CT, GA), AT #1 (AT, GG), AT #2 (AT, GG), CA #1 (TG, CA), CA #2 (TG, CA), CC #1 (GG, CC), CC #2 (GG, CC), CG #1 (CG, AA), CG #2 (CG, AA), CT #1 (AG, TT), CT #2 (AG, TT), GA #1 (TC, GA), GA #2 (TC, GA), GC #1 (GC, TT), GC #2 (GC, TT), GG #1 (CC, TT), GG #2 (CC, TT), GT #1 (AC, TG), GT #2 (AC, TG), TA #1 (TA, GG), TA #2 (TA, GG), TC #1 (GA, CT), TC #2 (GA, CT), TG #1 (CA, TG), TG #2 (CA, TG), TT #1 (AA, GG) and TT #2 (AA, GG). The ligated products were subsequently detected by PCR amplification using the primers PB547 (5′-gatcctctagagtcgacctg-3′) (SEQ ID NO: 1) and PB1073 (5′-cgggtaccgagctcgaattcttagaag-3′) (SEQ ID NO: 4). All primer sequences are listed in Table S1.

The measurement of the dinucleotide capture efficiency of each adaptor (FIGS. 2J-2K) was determined by ligating the 16 different adaptors to annealed oligonucleotides containing complementary dinucleotides. To mimic the 5′ phosphorylation induced by AcuI in DTECT experiments, the reverse oligonucleotide (PB1449: 5′-gtagttcgccagttCTTCAGaatagtttgcgca CAGGACGGGTCTCGTGAGGAATTGC-3′) (SEQ ID NO: 91) was phosphorylated with PNK (NEB). The phosphorylation reaction was conducted as follows: 5 μl of PB1449 (100 μM), 4 μl of 5× ligase buffer, 0.5 μl of PNK in a 20 μl reaction. Phosphorylation was obtained upon incubation for 1 hour at 37° C., followed by heat inactivation of PNK for 20 min at 65° C. After incubation, the phosphorylated oligonucleotide PB1449 was annealed to 16 complementary oligonucleotides with the following sequence: 5′-GCAATTCCTCACGAGACCCGTCCTGTGCGCAAACTAT TCTGAAGAACTGGCGAACTACNN-3′ (SEQ ID NOs: 231-246). The two Ns indicate the dinucleotide that is different for each of the 16 oligos, with N=A, C, G or T. In the annealing reaction, 40 μl of 5× ligase buffer and 130 μl of H₂O were added to the phosphorylation reaction. 9.5 μl of this mix were used for annealing with 0.5 μl of each of the above 16 oligos (50 μM). Annealing, which was performed as described above for the library of adaptors, resulted in a 5′-phosphorylated double-stranded DNA with an overhang of 2 nucleotides, mimicking the product of AcuI digestion. The ligation between the adaptors and the phosphorylated products was performed as follows: 1 μl of annealed oligonucleotides, 2 μl of T4 ligase buffer, 0.5 μl of T4 ligase and 0.5 μl of adaptors in a 10 μl reaction. The ligation reaction was incubated for 1 hour at 25° C. and 10 min at 65° C. Detection was performed using qPCR as described below in the DTECT protocol.

The assay performed to measure the efficiency of DNA ligation (FIG. 10F) was conducted in a master mix reaction equivalent to 5 μl per time point as follows: 0.5 μl of AcuI digested products, 1 μl of T4 ligase buffer and 0.5 μl of adaptors with or without 0.5 μl of T4 ligase. The reactions were incubated at 25° C. After 5 min, 5 μl were taken from the reaction and the T4 ligase was added for 10 min at 65° C. 1 hour after the start of the ligation reaction, 5 μl were additionally taken from the reaction and heat inactivated. The rest of the reaction was incubated overnight for 16 hours and heat inactivated. The amount of products captured was determined by qPCR as described below.

To calculate the frequency of non-specific dinucleotide capture shown in FIG. 10E, AcuI-generated fragments of WT SMARCAL1, SPRTN and PIK3R1 amplicons (obtained as described below) were ligated to each of the 16 library adaptors under the adaptor ligation conditions described above. The frequency of non-specific dinucleotide capture for all the adaptors non-complementary to the SMARCAL1, SPRTN and PIK3R1 dinucleotide signatures was calculated by qPCR analysis, as described below. Adaptors complementary to +1 and −1 AcuI-dependent slippage events were excluded from the analysis.

DTECT Protocol

The DTECT protocol consists of 6 steps (I-VI, FIG. 1A). I) Design of the AcuI-tagging primer, as described above. II) Amplification of the genomic locus of interest using the AcuI-tagging primer. The genomic DNA (gDNA) is prepared using the Quick Extract Solution (Epicentre) by incubating the cells at 65° C. for 10 min and 95° C. for 5 min. The genomic DNA is quantified by Nanodrop, diluted to 200 ng/μl in H₂O and stored at −20° C. or immediately used in PCR reactions. PCRs were performed in a 25 μl or 50 μl solution containing: 1 μM forward and reverse primers, 0.1 mM dNTP (NEB #N0447L), 1×Q5 buffer (NEB), 10-200 ng of gDNA, 1 unit of Q5 polymerase (NEB) and water. PCR reactions were conducted as follows: 95° C. for 30 s; 40 cycles of 95° C. for 10 s, 58° C. for 10 s, 72° C. for 45 s; and final amplification at 72° C. for 1 min. When the AcuI-tagging PCR did not work on gDNA (<5% of the cases), a PCR using standard locus-specific primers was performed to amplify the targeted locus and the AcuI-tagging PCR was conducted using this amplicon as template DNA. PCR products were loaded on a 2% agarose gel and run in TAE buffer. PCR products were extracted from gel and column purified (Zymo Research #D4008) and the purified products were subsequently quantified using Nanodrop. III) Digestion of the AcuI-tagged genomic amplicon with AcuI. The purified PCR products were digested by 0.25 μl AcuI (NEB #0641L) in a 20 μl reaction containing 1× CutSmart Buffer (NEB) supplemented with 40 μM S-adenosylmethionine (SAM) and 100 ng of purified PCR product. The reaction was incubated for 1 hour at 37° C. with heat inactivation at 65° C. for 20 min. IV) Isolation of the AcuI-digested genomic amplicon by solid phase reversible immobilization (SPRI). 10 μl of the digestion reaction were subsequently mixed with 18 μl of Agencourt AMPure XP magnetic beads (Beckman Coulter #A63881) by pipetting up and down the beads 10 times (volume ratio of DNA:beads=1:1.8) and then incubated at room temperature for 5 min. This procedure resulted in the binding of the larger digestion fragment (>100 bp) to the beads, while the smaller digested fragment (60 bp) remained in the supernatant. After incubation, the supernatant was isolated using a magnetic rack. 20 μl of the supernatant were recovered, diluted in 40 μl of H₂O and stored at −20° C. or immediately used for capture with DNA adaptors. V) Capture of the digested 60 bp-long products using DNA adaptors. The purified 60 bp-long DNA fragments were ligated to DNA adaptors generated as described above. The adaptors and the purified products were ligated in the following reaction: 6.5 μl of water, 2 μl of 5× ligase buffer (ThermoFisher Scientific), 0.5 μl of T4 ligase (ThermoFisher Scientific), 0.5 μl of adaptors and 0.5 μl of purified DNA product. The ligation reaction was performed for 1 hour at 25° C. in a thermocycler, followed by inactivation of the T4 ligase for 10 min at 65° C. The ligated products were stored at −20° C. or used directly for detection of the captured material. VI) Analytical or quantitative detection of the captured DNA products by PCR amplification. For analytical detection, the amplification of the captured material was performed by PCR in a 12.5 or 25 μl reaction volume containing 0.5 μM forward and reverse primers, 0.05 mM dNTP (NEB #N0447L), 1×Q5 buffer (NEB), 0.5-1 μl of ligated product, 0.1-0.2 μl of Q5 polymerase (NEB), 0.5-1 μl ligation reaction and water. PCR primers (PB1072 and PB1073) contained sequences complementary to the adaptor and handle (see above). The PCR program used was the following: 95° C. for 1 min, and different number of cycles (indicated in each figure legend) of 95° C. for 10 s, 65° C. for 5 s, 72° C. for 7 s. Detection of low abundant genomic variants (≤1% frequency) was generally obtained with 23-25 PCR cycles, while detection of greater amounts of edited products was achieved with 17-22 PCR cycles. 5 μl of the PCR reactions were incubated with SYBR Gold (Thermofisher Scientific #S-11494), loaded on a 2% agarose gel and run in 1×TAE buffer until the DNA was separated. Gels were developed using LI-COR Odyssey. qPCR was performed using QuantStudio 3 (Applied Biosystems). qPCR reactions were performed as follows: 5 μl of 2×SYBR Gold master mix (ThermoFisher Scientific #4367659), 0.1 μl of forward and reverse primers (PB1072 and PB1073, 100 μM) and 1 μl of ligated products (diluted 1:100 in H₂O) in a 10 μl reaction. The PCR program used in the qPCR reaction was the following: 95° C. for 10 s and 40 cycles of 60° C. 30 s, 95° C. 15 s. Quantification of the frequency of genomic variants was conducted as described below (Quantification and Statistical Analysis section).

Next-Generation Sequencing

Samples for NGS were prepared by amplifying the edited regions of interest by PCR. Samples were sequenced by the Genome Sciences Facility at The Pennsylvania State College of Medicine or by Genewiz and the results were analyzed by Genewiz, or by using an R-based script of the Ciccia laboratory or CRISPResso2 (Clement et al., 2019). To ensure that no biases were introduced during DTECT assays, the AcuI-tagging amplicons for the BRCA1 and BRCA2 mutant samples were sequenced by NGS and analyzed using an R-based script. In this analysis, 7 sequences with >6000 reads were filtered out from the analysis due to incorrect sequence. The editing frequency from the NGS results were determined using the formula: ((Number of reads for the edited dinucleotide)/(total number of reads))×100. Oligonucleotides used for PCR amplifications, Illumina sequencing adaptors and indexes are listed in Table S1.

Quantification and Statistical Analysis

Technical duplicates of each sample were performed in each qPCR reaction. A standard curve to determine the concentration of the captured material was generated using predefined concentrations of a DTECT ligation product (FIG. 1A, step V) cloned into the pCR-Blunt II-TOPO vector (ThermoFisher Scientific; B650 plasmid, Addgene #139333) and oligos PB1072 and PB1073 (Table S1). The calculated standard curve corresponds to a linear curve with the following parameters: y=−3.3245×+7.5504 and R²=0.99819. Quantification of the frequency of genomic variants was determined by calculating the mean Ct score (Mean Ct) of the two technical duplicates for each sample. The concentration of the captured material for each sample was determined using the following formula: Concentration=10{circumflex over ( )}((Mean Ct −7.5504)/-3.3245). The relative abundance between WT and mutant signatures was determined as follows: Frequency^(Mutant)=(Concentration^(Mutant)/(Concentration^(Mutant)+Concentration^(WT)))×100 and Frequency^(WT)=(Concentration^(WT)/(Concentration^(Mutant)+Concentration^(WT))×100.

Data and Code Availability

R-based scripts of the Ciccia laboratory for analysis of NGS reads and ClinVar datasets are available upon request. Raw NGS reads of edited DLD1 and NIH/3T3 cells, organoids and liver samples are available under accession SRP151111 in the Sequence Read Archive. NGS reads have been deposited into the NCBI database and are and are accessible as BioProject #PRJNA603357. All uncropped gels, raw qPCR data and Sanger sequencing reads are available in Mendeley (https://data.mendeley.com/datasets/gtkk6sthtw/draft?a=ca72630e-56eb-4e29-bcdb-158b2c7d4123).

KEY RESOURCES TABLE REAGENT or RESOURCE SOURCE IDENTIFIER Bacterial and Virus Strains Subcloning Efficiency DH5α ThermoFisher 1 8265-017 Scientific Chemicals, Peptides, and Recombinant Proteins Q5 High-Fidelity DNA polymerase NEB M0491L T4 DNA ligase ThermoFisher 15224017 Scientific Acul NEB R0641L rSAP NEB M0371L SybrGold (for gel staining) ThermoFisher S-11494 Scientific SybrGold (for qPCR) ThermoFisher 4367659 Scientific BamHI-HF NEB R3136S dNTPs NEB N0447L T4 Polynucleotide Kinase NEB M0201S Critical Commercial Assays Agencourt AMPure XP magnetic beads Beckman Coulter A63881 Zymoclean gel DNA recovery kit Zymo Research D4008 Quick Extract DNA Extraction Solution Epicentre QE09050 Zero BLUNT II TOPO PCR Cloning kit ThermoFisher 450245 Scientific Deposited Data Unprocessed images of gels This disclosure, Raw gel images Mendeley Data Raw Sanger sequencing files This disclosure, Sequences of Mendeley Data BRCA1-2 edited cells; Repeated sequences Raw NGS sequencing files This disclosure, BioProject # NCBI PRJNA603357 Raw and processed qPCR data This disclosure, Raw and Mendeley Data processed qPCR data Raw and processed DTECT, ICE, EditR and This disclosure, Quantification of NGS data Mendeley Data BRCA1-2 variants by DTECT, ICE, EditR and NGS Experimental Models: Cell Lines Human: HEK293T ATCC CRL-11268 Human: DLD1 ATCC CCL-221 Mouse: NIH/3T3 ATCC CRL-1658 Experimental Models: Organisms/Strains Mouse: C57BL/6N Charles River C57BL/6NCrl Mouse: Brca1^(S1598F/+) Shakya et al, 2011 N/A Mouse: Bard1^(S563F/+) Billing et al, 2018 N/A Mouse: Mx1Cre⁺; CD45.1 Mullally et al, 2010 N/A Mouse: Mx1-Cre⁺; CD45.2 Jak2^(V617F/+) Mullally et al, 2010 N/A Mouse: NRG The Jackson 007799 Laboratory Oligonucleotides Primers for PCR This disclosure Table S1 Oligonucleotides for sgRNA cloning This disclosure Table S1 ssODNs (for HDR) This disclosure Table S1 Oligonucleotides for adaptors This disclosure Table S1 Recombinant DNA Plasmid: B52 (containing 2 empty sgRNAs- Addgene 100708 expressing cassettes) pCMV-PE2 Addgene 132775 pCMV-BE3 Addgene 73021 DTECT - Plasmid for standard curve This disclosure, 139333 Addgene pTOPO-SPRTN WT This disclosure N/A pTOPO-SPRTN STOP This disclosure N/A pTOPO-SMARCAL1 WT This disclosure N/A pTOPO-SMARCAL1 STOP This disclosure N/A pTOPO-PIK3R1 WT This disclosure N/A pTOPO-PIK3R1 STOP This disclosure N/A pX330-U6-Chimeric_BB-CBh-hSpCas9 Addgene 42230 pCDNA3-Flag::UbvG08 I44A, deltaGG Addgene 74939 pU6-Sp-pegRNA-HEK3-CTT_ins Addgene 132778 Plasmids expressing sgRNAs for base editing This disclosure, 139321-139332, of FANCD2, BRCA1 and BRCA2 Addgene and 139511 Software and Algorithms R Studio Desktop IDE 1.0.143 RStudio https://www.rstudio.com Bioconductor R packages Bioconductor https://www.bioconductor.org R 3.4.1 The R project for https://www.r-project.org statistical computing Other ClinVar database NCBI https://www.ncbi. nlm.nih.gov/clinvar/ Li-COR Odyssey N/A https://www.licor. com/bio/products/ imaging_systems/ odyssey q-PCR QuantStudio 3 Applied N/A Biosystems

Example 2 Design of DTECT, a Detection Method Based on the Capture of Dinucleotide Signatures

In our detection method, we take advantage of the property of type IIS restriction enzymes to generate single-stranded DNA overhangs at a specific distance from their recognition motif. Based on the above property, we hypothesized that single-stranded DNA overhangs generated by digestion of genomic DNA sequences with type IIS restriction enzymes could be captured and identified using DNA adaptors containing overhangs complementary to the exposed DNA signatures (FIG. 1A). To identify type IIS enzymes with efficient and accurate endonuclease activity, we analyzed the properties of known type IIS enzymes. Restriction enzymes optimal for our method exhibit the following characteristics: a) they cleave far from their recognition motif, thus enabling the incorporation of non-complementary type IIS recognition motifs into PCR primers without disrupting genomic DNA amplification (FIGS. 1A and 8A); b) they bind a single recognition motif (Bath et al., 2002) (FIG. 8A); and c) they possess highly specific endonuclease activity, therefore generating a limited number of cleavage byproducts due to slippage activity (Lundin et al., 2015) (FIG. 8B). Among the >40 known type IIS endonucleases, only 6 enzymes cleave at a distance bp from their recognition motif (AcuI, BpmI, BpuEI, BsgI, MmeI and NmeAIII) (FIG. 8C). Of those enzymes, only AcuI and BpuEI have a single recognition motif, and AcuI exhibits the lowest slippage activity of the two enzymes (slippage byproducts: AcuI, 1.1%; BpuEI, 41.4%) (Lundin et al., 2015). In particular, upon DNA cleavage AcuI exposes a dinucleotide signature located 15/16 nucleotides away from its recognition site (FIG. 8D). Based on the above considerations, AcuI is the most suitable restriction enzyme for our detection method.

In our approach, the genomic locus of interest is PCR-amplified using a locus-specific DNA primer (red) and a DNA oligonucleotide (AcuI-tagging primer) containing two regions of complementarity to the genomic locus (purple) interrupted by an AcuI recognition site (AcuI hairpin, green) positioned 14 bp upstream of a dinucleotide of interest (FIG. 1A, steps I and II). Tagging of the genomic amplicon with an AcuI motif allows AcuI-mediated digestion of the sequence of interest on the 3′-side of the targeted dinucleotide. Upon AcuI-mediated digestion, the signature of the targeted dinucleotide becomes exposed (FIG. 1A, step III). To proceed with a single DNA fragment containing the targeted dinucleotide, the larger DNA fragment (>100 bp) resulting from AcuI-mediated digestion is removed using solid phase reversible immobilization (SPRI) beads (FIG. 1A, step IV) and the smaller DNA fragment (60 bp) containing the targeted dinucleotide is ligated to an adaptor with a 3′-overhang complementary to the exposed signature (FIG. 1A, step V). The ligated DNA products are subsequently detected by analytical or quantitative PCR (qPCR) (FIG. 1A, step VI). This method, which we named DTECT (Dinucleotide signaTurE CapTure), can be completed within 4-5 hours (FIG. 1A). A common set of DNA primers that anneal to constant regions in the AcuI-digested fragments (blue) and the ligated adaptors (brown) is utilized in all DTECT experiments (FIG. 1A, step VI), avoiding locus-specific amplification bias and variability in qPCR efficiency among distinct sets of samples. Considering the total number of 16 unique dinucleotides (2⁴), a library of 16 distinct adaptors is sufficient to capture all dinucleotide signatures that can be generated by AcuI (FIG. 1B). Given the possible use of positive and negative controls to determine the efficiency and specificity of dinucleotide capture (FIG. 1C), DTECT provides a highly controlled assessment of successful and specific capture of dinucleotide signatures

Example 3 DTECT Efficiently Captures Dinucleotide Signatures Generated by AcuI-Mediated Digestion

To demonstrate the feasibility of DTECT, we designed two AcuI-tagging DNA primers flanking four adjacent bases (5′-TTGG-3′) on opposite DNA strands (TT and CC signatures, blue) (FIG. 2A). Upon PCR amplification using AcuI-tagging primers and locus-specific DNA primers, the PCR amplicons were digested and ligated to adaptors with either complementary or non-specific 3′-overhangs (GG or AA). Detection of the ligated products by PCR, as described above, revealed that the GG and AA adaptors specifically captured the DNA fragments containing the CC and TT dinucleotides, respectively (FIG. 2B). Sanger sequencing confirmed that the amplicons of the ligated DNA products had the expected genomic sequence (purple) adjacent to the AcuI motif (green) and the GG or AA adaptors (brown) (FIGS. 9A-9B). Importantly, robust amplification of captured DNA products was observed only upon 1) capture of the AcuI-digested products with complementary adaptors (FIG. 2B), 2) AcuI-mediated cutting and generation of 5′-phosphorylated DNA fragments (FIGS. 2C-2D), and 3) DNA ligation by the T4 DNA ligase (FIG. 2D). We additionally showed that each individual DNA base can be identified by designing 4 independent AcuI-tagging primers (2 on each DNA strand), thus enabling the capture of 4 distinct signatures per genomic DNA base (FIGS. 2E-2F). This DTECT feature allows flexible AcuI-mediated cleavage of genomic DNA amplicons containing targeted DNA sequences. In additional studies, we confirmed that each of the 16 possible dinucleotide signatures generated by AcuI at two independent target sites can be efficiently captured using DNA adaptors containing complementary DNA overhangs (FIG. 9C). Together, these studies establish DTECT as a rapid and efficient method to identify DNA bases through the capture of AcuI-induced dinucleotide signatures using a common and unique set of adaptors.

Example 4 DTECT Enables Specific and Sensitive Quantification of DNA Variants

Next, we examined whether DTECT can determine the relative abundance of DNA variants with distinct DNA signatures, including low abundance DNA variants. To this end, we transfected HEK293T cells with sgRNAs that introduce nonsense mutations into the SPRTN, PIK3R1 and SMARCAL1 genes using iSTOP, a CRISPR-mediated base editing approach that creates STOP codons within genes of interest (Billon et al., 2017) (FIG. 10A). We then cloned both WT and mutant alleles, which differ by a single base change (C->T) (FIG. 10B), and subjected them to PCR amplification using a locus-specific DNA primer and an AcuI-tagging primer flanking the iSTOP-targeted DNA base (FIG. 10C). The WT and edited PCR products were then mixed at different ratios (WT−STOP allele=100-0, 99-1, 90-10, 75-25, 50-50, 25-75 or 10-90) and digested with AcuI. The resulting DNA fragments were then captured using adaptors complementary to WT (green) and STOP (purple) dinucleotide signatures (FIG. 10A). Remarkably, qPCR analysis of the captured DNA fragments accurately determined the relative abundance of the WT and STOP alleles at the three loci indicated above (FIG. 2G), demonstrating that DTECT can estimate the frequency of dinucleotide signatures in a mixed population with high precision, including variants with low abundance (1%) (FIG. 2G). Low abundance STOP variants in SPRTN and PIK3R1 were also detectable by analytical PCR (FIGS. 2H-2I and 10C-10D), confirming the high sensitivity and accuracy of DTECT. Importantly, direct comparison of the 16 DTECT adaptors revealed comparable efficiency in the capture of oligonucleotides containing complementary dinucleotide signatures (FIGS. 2J-2K). In addition, all adaptors exhibited low levels of non-specific capture background (mean=0.325%, ranging from 0.16% to 0.876%) (FIG. 10E). The above observations indicate that the adaptor ligation is conducted under optimal conditions, as confirmed by kinetic analysis of the adaptor ligation reaction (FIG. 10F). Together, these findings demonstrate that DTECT captures dinucleotide variants and quantifies their relative abundance with high specificity and sensitivity.

Example 5 DTECT Accurately Identifies Genomic Changes Introduced by CRISPR-Dependent HDR, Base Editing and Prime Editing in Mammalian Cells

To examine the ability of DTECT to identify precise genomic changes introduced into mammalian cell populations, we utilized CRISPR-mediated HDR for generating various types of disease-related mutations using single-stranded oligodeoxynucleotides (ssODNs), including a cancer-associated frameshift mutation in TP53 (i.e., R209fs*6), a missense mutation in HBB (i.e., G6V) that causes sickle cell anemia, a small tandem duplication in BRCA2 (dupAGAAGAT) identified in breast cancer, and small insertions into JAK2 and EMX1 (Paulsen et al., 2017), two genes associated with myeloproliferative disorders and Kallmann syndrome, respectively. Three days after co-transfection of Cas9 with site-specific sgRNAs and ssODNs into HEK293T cells, we harvested the cellular genomic DNA and utilized DTECT to determine by analytical and quantitative PCR whether the desired changes were incorporated into the targeted chromosomal loci (FIG. 3A). For comparison, a restriction fragment length polymorphism (RFLP) assay that monitors restriction sites disrupted or created by the above mutations in the targeted genomic loci was conducted in parallel. In these experiments, DTECT readily captured the specific signature of the mutant variants (FIGS. 3B and 11A-11C), while the RFLP assay either failed to detect or weakly detected the same mutant variants (FIGS. 11F-11H). In addition, DTECT was able to discern the HDR stimulatory effect induced by i53 (FIGS. 3B and 11A-11B), a genetically-encoded 53BP1 inhibitor that was previously shown to increase the frequency of HDR events (Canny et al., 2018), indicating that DTECT can be employed to compare the editing levels between distinct experimental conditions. Importantly, DTECT also clearly determined which mutations failed to be incorporated by the HDR machinery (e.g., BRCA2 dupAGAAGAT), as confirmed by NGS analysis (FIGS. 11D-11E). Next, to determine whether DTECT can identify precise genomic changes introduced by CRISPR-mediated base editing in mammalian cell populations, we used a cytidine base editor to install nonsense mutations into the Fanconi anemia-associated genes FANCD2, FANCM and SLX4, the DNA replication and circadian clock gene TIMELESS and the Treacher Collins syndrome gene TCOF1. These experiments showed that DTECT was able to capture the signatures of the newly introduced variants in all of the above genes (FIGS. 3B and 11I-11J). Finally, to test whether DTECT is also able to identify genomic signatures generated by prime editing, we transiently transfected into HEK293T cells a prime editor and a pegRNA to introduce a 3-bp insertion (CTT_ins) in the HEK3 locus (Anzalone et al., 2019). As shown in FIG. 3B, DTECT specifically identified the newly created signature and quantified its frequency in the transfected cell population, indicating that DTECT is also suitable to identify prime editing events. The specificity and accuracy of the above DTECT studies was confirmed by both positive and negative controls (e.g., CG and TT adaptors in the control unedited sample of FIG. 3B).

To further confirm the accuracy of DTECT in quantifying precision genome editing, we compared the frequency of editing events determined by either DTECT or NGS across 62 samples derived from human cells, mouse cells and intestinal organoids, which were modified using CRISPR-mediated HDR or base editing (Zafra et al., 2018). As shown in FIGS. 3C (left panel) and 12A, the frequencies of editing events obtained by DTECT and NGS were comparable (mean frequency: DTECT, 35.43%; NGS, 33.47%; r=0.9857, n=62), indicating that the quantification of precision genome editing by DTECT is accurate. Similar to NGS, DTECT is also accurate in the detection of less abundant (<20% frequency) variants (mean frequency: DTECT, 5.41%; NGS, 5.06%, r=0.843, n=33) (FIG. 3C, right panel). Together, these experiments demonstrate that DTECT precisely identifies and quantifies genetic variants introduced by precision genome editing in various biological systems.

Recent studies led to the development of Sanger sequencing-based methods, such as ICE (Synthego; https://ice.synthego.com/#/) or EditR (Kluesner et al., 2018), that enable the detection of genomic variants based on the deconvolution of chromatogram peaks. To compare DTECT with the above methods, we subjected to Sanger sequencing the genomic amplicons of 23 samples edited by precision genome editing. In these experiments, we used two primers annealing to opposite DNA strands to obtain independent sequencing duplicates of the same amplicons, and analyzed the Sanger sequencing reads using either ICE or EditR. Notably, ˜10% of the sequencing reactions failed to generate high quality reads required for ICE or EditR, despite using high quality amplicons for sequencing (Mendeley dataset, Data availability section). Independent repeats using new genomic amplicons did not improve the sequencing outcome (Mendeley dataset, Data availability section). In addition, we noted that technical duplicates of Sanger sequencing reactions analyzed by ICE or EditR displayed lower levels of consistency relative to technical replicates of DTECT assays (FIG. 12B). These studies indicate that DTECT displays greater robustness and reliability compared to Sanger-based detection methods, which heavily rely on the quality of Sanger sequencing reactions.

Example 6 DTECT Enables the Identification of Precision Genome Editing Events In Vivo

The modeling and correction of pathogenic mutations in adult mice is critical for the development of novel approaches to therapeutic intervention against cancer and other diseases (Chadwick et al., 2017; Gao et al., 2018; Levy et al., 2020; Ryu et al., 2018; Song et al., 2020; Villiger et al., 2018; Yin et al., 2016; Yin et al., 2014). To determine whether DTECT can determine editing levels in adult mouse tissue, we hydrodynamically delivered into the mouse liver (Tschaharganeh et al., 2014) a cytidine base editor and an sgRNA introducing the oncogenic Pik3ca E545K mutation (Zafra et al., 2018) (FIG. 3D). We then used both DTECT and NGS to quantify the oncogenic Pik3ca signature in DNA samples derived from the edited livers of two mice. DTECT analysis identified base editing events in the mouse liver at a ˜1-2% frequency, comparable to the editing rates obtained by NGS (FIG. 3E). This study revealed that DTECT can accurately quantify low abundance genetic variants introduced by precision genome editing in vivo.

Example 7 DTECT is Capable of Identifying Multiple Genome Editing Events Occurring within a Single Locus or Distinct Loci

The above studies indicate that DTECT can determine the identity of individual genomic changes. To examine whether DTECT can also identify complex sets of mutations, we employed CRISPR-dependent base editing to target two adjacent cytosines in the EMX1 locus that had previously been converted into four distinct dinucleotide combinations (i.e., CC, CT, TC or TT) by base editing (Komor et al., 2016) (FIG. 4A). As shown in FIG. 4A, DTECT readily distinguished each of the four combinations in an sgRNA-dependent manner, demonstrating that DTECT can identify a complex mixture of allelic variants. Furthermore, we also detected base editing byproducts (FIG. 13A), suggesting that DTECT could be used to optimize conditions that reduce the formation of these byproducts (Komor et al., 2017; Wang et al., 2017). Additionally, to determine whether DTECT can be employed to monitor genomic changes at multiple loci, we simultaneously introduced two clinically relevant point mutations into two distinct genes (i.e., BRCA1 and BRCA2) (FIG. 4B). As shown in FIG. 4C, DTECT correctly identified these genomic changes, indicating that it can readily detect complex genome editing events occurring within single or multiple genomic loci.

Example 8 DTECT Expedites the Derivation of Marker-Free Cell Lines Carrying Clinically Relevant Mutations and Facilitates the Genotyping of Cellular and Animal Disease Models

Precision genome editing allows the modeling of clinically relevant gene variants. Given that DTECT enables the identification of newly created DNA signatures without requiring the insertion of markers or elaborate experimental design specific for each edited site, we tested whether DTECT could facilitate the generation of multiple cell lines harboring clinically relevant mutations. In particular, we focused our attention on mutations in the BRCA1 and BRCA2 genes, which in heterozygosity can predispose women to the development of breast and/or ovarian cancer (Apostolou and Fostira, 2013), whereas in homozygosity can cause Fanconi anemia (Ceccaldi et al., 2016). More than 7,000 clinically associated SNVs have been identified in BRCA1/2, according to the ClinVar database, but efforts to characterize their functional impact and pathogenic potential have been limited in part due to the challenge of generating cell lines that carry such a large number of individual homozygous and heterozygous variants. To determine whether DTECT can facilitate the production of cell lines harboring clinically relevant BRCA1/2 SNVs, we expressed a cytidine base editor in HEK293T cells along with individual sgRNAs to generate 23 different BRCA1/2 mutations identified in patients with ovarian and breast cancers, as reported in ClinVar (FIGS. 5A and 5D). We then used DTECT to determine by analytical PCR which variants were introduced in the transfected cell populations and quantify the editing efficiency for each variant by qPCR (FIGS. 5B-5C, 5E-5F and 13B-13C). The accuracy of DTECT in the quantification of the editing events was confirmed by NGS (FIGS. 5B and 5E). The above approach proved effective for rapidly identifying cell populations with high levels of editing. Upon isolation of single clones from edited cell populations (e.g., BRCA1 E638K mutant cells), we tested whether DTECT could be used for clone genotyping. Importantly, DTECT allowed rapid genotyping of multiple clones (FIG. 14A) and accurately determined the genotype of each clone, including WT, homozygous and heterozygous mutant clones (FIGS. 5G-5H), thus expediting the production of marker-free isogenic heterozygous and homozygous mutant cells.

Given the ability of DTECT to correctly determine the genotype of cellular clones, we then tested whether DTECT could also be applied to mouse genotyping. To this end, we obtained tail DNA samples from genetically engineered mice carrying knock-in mutations in Brca1 (S1598F) and its partner protein Bard1 (S563F) (Billing et al., 2018). As shown in FIGS. 5I-5J and 14B, DTECT accurately determined the genotype of 24 Bard1 S563F mutant mice and 16 Brca1 S1598F mutant mice. These findings indicate that DTECT can be employed to rapidly determine the genotype of genetically engineered mice, thus facilitating the derivation, maintenance and analysis of marker-free animal models.

Example 9 DTECT Identifies the Presence of Oncogenic Mutations in Cancer Mouse Models and Human Cancer Patient Samples

Precise and rapid detection of pathogenic variants in patients is critical for accurate diagnosis and personalized therapy. Given the ability of DTECT to identify genetic variants rapidly and accurately, we tested whether DTECT could be utilized to expedite the identification of pathogenic variants in pre-clinical and clinical settings. In particular, we examined whether DTECT could identify the presence of oncogenic variants in various biological systems. In our studies we focused our attention on the JAK2 V617F variant, which is present in the majority of patients with myeloproliferative neoplasm (MPN) (Levine et al., 2005). Mice transplanted with Jak2 V617F mutant bone marrow cells develop MPN and recapitulate the human disease (Mullally et al., 2010). Therefore, we analyzed the Jak2 V617F variant in the peripheral blood of mice transplanted with a mixture of bone marrow cells that do or do not carry an inducible Jak2 V617F variant (Bhagwat et al., 2014) (FIG. 15A). As shown in FIGS. 15B-15C, DTECT readily distinguished wild-type from V617F mutant Jak2 in the examined mouse blood samples, as detected using any of the four distinct AcuI-tagging primers specific for the targeted bases. These experiments show that DTECT can identify oncogenic signatures of interest in mouse tissues in a marker-free manner, thus enabling the tracking of genetic variants in mouse models without requiring complex selection markers.

We next examined whether DTECT can identify the presence of specific oncogenic mutations in human samples from patients diagnosed with acute lymphoblastic leukemia (ALL), the most common form of childhood cancer (Inaba et al., 2013). Although most ALL patients respond to chemotherapy, ˜20% suffer a relapse as a result of resistance to chemotherapy (Bhojwani and Pui, 2013). Moreover, secondary genetic alterations that promote chemoresistance, including mutations in the NT5C2 gene (Tzoneva et al., 2018; Tzoneva et al., 2013), are found in a large fraction of ALL relapse cases (Dieck and Ferrando, 2019; Oshima et al., 2016). To test whether DTECT can identify these relapse-specific oncogenic signatures, we obtained matched DNA samples from the bone marrow of ALL patients at diagnosis and relapse and analyzed them for the presence of three common NT5C2 mutations (R238W, K359Q and R367Q) (FIGS. 6A-6B). Remarkably, DTECT unambiguously detected the presence of oncogenic NT5C2 variants in all five patient samples (patient #1, R238W; patients #2, #4 and #5, R367Q; patient #3, K359Q) and accurately quantified their frequency in a manner comparable to NGS (FIGS. 6B-6C and 15D). Moreover, DTECT also identified the presence of the above NT5C2 variants in the patient-derived xenograft (PDX) models generated from these relapsed ALL patients (FIGS. 6A and 6D). These studies demonstrate that DTECT can identify oncogenic mutations of interest in PDX models and cancer patient samples.

Example 10 Discussion

In this study, we established DTECT as a sensitive method for the identification of genomic DNA signatures. In particular, we show that DTECT readily identifies precision genome editing events induced by CRISPR-dependent HDR, base editing and prime editing, including low abundance and complex genomic changes. In addition, we show that DTECT can be employed to identify pathogenic lesions of interest, such as oncogenic mutations, in cancer mouse models, PDXs, and cancer patient specimens. DTECT is a rapid (˜4-5 hours) and easy-to-perform detection method that relies on standard molecular biology techniques (PCR, DNA digestion and ligation) and common laboratory reagents. This methodology is also not labor-intensive, given that it entails short periods (5-10 min) of sample processing followed by hands-free incubations. Importantly, DTECT assays utilize a unique and common set of adaptors that includes positive and negative controls to ensure specificity and accuracy. The ease, speed and cost efficiency by which DTECT identifies genetic variants in a wide variety of cellular and animal systems (e.g., cell lines, organoids, animal models, patient samples) should facilitate the generation and study of biological models of human diseases and expedite the detection of pathogenic variants for both pre-clinical and clinical applications.

Although highly robust, DTECT has three potential limitations. First, AcuI-induced dinucleotide byproducts can be generated if a genomic AcuI restriction site located in close proximity to the targeted dinucleotide is incorporated into the amplicon of the targeted locus. However, an analysis of the ClinVar database revealed that genomic AcuI sites occur relatively infrequently and 95% of clinically relevant variants (404,393 variants) are compatible with DTECT (FIGS. 16A-16B). Second, dinucleotide byproducts may also occur due to AcuI slippage activity, resulting in the cleavage of DNA molecules 13 (−1) or 15 (+1), instead of 14, bases away from the AcuI recognition site. Nonetheless, we found that DTECT is able to identify AcuI slippage events, which occur mostly at position +1 relative to the standard AcuI cleavage site (Lundin et al., 2015) (FIG. 17A). It is reasonable to anticipate that future optimization of AcuI architecture and improvements in the AcuI digestion protocol will limit its slippage activity. It is also important to note that AcuI byproducts resulting from either genomic AcuI motifs or AcuI slippage activity are easily predictable based on the sequence of the nucleotides flanking the targeted dinucleotide and they can be completely avoided by optimal design of the AcuI-tagging primer and appropriate adaptor selection, as shown in FIGS. 16C and 17B. Third, indel mutations formed at DSB sites generated by Cas nucleases in CRISPR-mediated HDR experiments can result in defective PCR amplification of indel-containing loci that have not undergone HDR and therefore cause an overestimation of the frequency of HDR events by DTECT (FIGS. 18A and 18B). However, given that the mutagenic spectrum of indel mutations induced by any sgRNA is predictable (Allen et al., 2018; Leenay et al., 2019; Shen et al., 2018; van Overbeek et al., 2016) (inDelphi web portal; https://indelphi.giffordlab.mit.edu/), the negative impact of indel mutations on DTECT-based quantification of CRISPR-mediated HDR events can be avoided by introducing the desired genomic changes in indel-free regions adjacent to CRISPR-induced cut sites (FIGS. 18C and 18D). This limitation does not affect the detection of CRISPR-mediated base editing and prime editing events, and naturally occurring genetic variants, which are accompanied by either very low frequency (Anzalone et al., 2019; Gaudelli et al., 2017; Komor et al., 2017; Yeh et al., 2018) or complete absence of DSB-induced indel formation, respectively.

In addition to its ease of use, speed and cost efficiency, DTECT has several advantages compared to other detection methods. A major benefit of DTECT is its versatility, which allows the detection and quantification of nucleotide substitutions, precise base insertions and deletions using the same small set of 16 predefined adaptors (FIGS. 1B and 7). Each editing event can be identified using 4 distinct signatures resulting from AcuI-mediated digestion of genomic DNA amplicons, indicating that the design of DTECT studies is flexible (FIGS. 2E-2F and 15B-15C). These features distinguish DTECT from strategies that employ allele-specific DNA oligonucleotides or probes to identify SNVs, which work with variable efficiency due to the competition between WT and mutant alleles and the number of variant DNA bases, thus requiring unique experimental design for the detection of each individual genetic variant. Given that both wild-type and mutant DNA signatures are captured from the same AcuI-digested PCR amplicon and that a common set of PCR primers is utilized for both analytical and quantitative detection of all variants (FIG. 1A, step VI), DTECT exhibits limited technical variability across distinct experimental conditions. This aspect differentiates DTECT from Sanger sequencing-based detection methods, such as ICE and EditR, in which efficiency depends on the quality of the sequencing reads, which can vary greatly between sequencing platforms, samples and reactions (FIG. 12B). In addition, DTECT displays greater sensitivity and flexibility compared to RFLP-based assays (FIGS. 11A-11J) and exhibits similar precision to NGS (FIG. 3C) at a lower cost and with a faster turnaround time (hours vs. days/weeks). Finally, DTECT directly identifies genetic variants independently of genomic markers, therefore enabling the analysis of scarless and marker-free cellular and animal models generated by precision genome editing. Given its ability to identify multiple independent genetic variants simultaneously (FIGS. 4A-4C), DTECT could expedite the generation of complex genomic changes, especially for genetic interaction studies, synthetic biology applications and molecular recording (Fahim Farzadfard, 2018).

The ability to model clinically relevant mutations in a marker-free manner is critical for assessing their potential pathogenicity, especially in the case of genes, such as BRCA1 and BRCA2, which have thousands of clinically-associated SNVs. Recent studies have led to the development of high-throughput saturation genome editing (SGE) to examine en masse the pathogenicity of BRCA1 variants (Findlay et al., 2018). Although highly useful for classifying BRCA1 SNVs, SGE requires the use of haploid cells and is therefore not compatible with the study of the functional impact of BRCA1 mutations in heterozygosity, as observed in BRCA1 mutation carriers (Apostolou and Fostira, 2013). BRCA1/2 heterozygous mutations have been recently shown to cause genome instability induced by DNA replication stress (Billing et al., 2018; Pathania et al., 2014; Tan et al., 2017). By facilitating the derivation of both heterozygous and homozygous BRCA1/2 mutant cells and animal models (FIGS. 5A-5J), DTECT could help elucidate the underlying mechanisms by which genome instability causes breast and ovarian cancer development in BRCA1/2 mutation carriers. Our work demonstrated that DTECT can expedite the generation of a large variety of human genetic variants in various complex biological systems.

In addition to facilitating precision genome editing, we showed that DTECT can also be used to detect pathogenic variants in pre-clinical and clinical settings. In particular, DTECT can rapidly identify the presence of oncogenic variants in cancer mouse models (FIGS. 15A-15D), thus facilitating the study of cancer pathogenesis and the development of novel cancer therapies. Furthermore, DTECT can also identify oncogenic mutations in samples from cancer patients and PDX mouse models (FIGS. 6A-6D). The speed by which DTECT accurately and unambiguously identifies pathogenic variants could accelerate cancer diagnosis and expedite the testing of cancer therapies in PDX models, thus leading to more effective cancer treatments. We envision that future developments and implementations of the DTECT protocol may further simplify the detection of desired genomic signatures and increase the sensitivity of DTECT, thus expanding the number of possible DTECT applications and enabling early diagnosis of cancer and hereditary disorders through the detection of pathogenic variants in circulating cell-free tumor and fetal DNA (Zhang et al., 2019).

Collectively, our work established DTECT as a facile, rapid and cost-effective method for identifying genomic variants in various biological systems, such as mammalian cell lines, organoids, mouse tissues, PDX models and human patient samples. Given the growing number of genetic variants identified in the human population (Lek et al., 2016) and in human genetic disorders (McClellan and King, 2010), this versatile method for the detection of genomic signatures should facilitate the study of human genetic variation and expedite the diagnosis and treatment of human disease.

TABLE S1 Primers, ssODNs, adaptors and other oligos used in this disclosure. Detection primers Sequence (5′- -> 3′) Notes PB547 gatcctctagagtcgacctg (SEQ ID NO: 1) Oligos for detection (step VI) PB548 cgggtaccgagctcgaattc (SEQ ID NO: 2) Oligos for detection (step VI) PB1072 gcaattcctcacgagacccgtcctg (SEQ ID NO: 3) Oligos for detection (step VI) - Only these oligos were used for qPCR PB1073 cgggtaccgagctcgaattcttagaag (SEQ ID NO: 4) Oligos for detection (step VI) - Only these oligos were used for qPCR AcuI- tagging Sequence (5′- -> 3′): Handle for  primers detection-gDNA-AcuI hairpin-gDNA Notes PB1021 gatcctctagagtcgacctgGGAGTCCCTGTCGCTAGTGG AcuI for signature CTGAAGACGCGTCGTGGGAG (SEQ ID NO: 5) TT PB1022 gatcctctagagtcgacctgACAAACAGTGCCTGCAAGTCC AcuI for signature TGAAGCGGTGTGGGGTCCA (SEQ ID NO: 6) CC PB1071 GCAATTCCTCACGAGACCCGTCCTGATTTCAGGG AcuI for PIK3R1- AAGAAGCTGAAGTGAATGAAAAACTT (SEQ ID NO: STOP 7) PB1153 GCAATTCCTCACGAGACCCGTCCTGTGTAGTTTTA AcuI for JAK2 CTTACCTGAAGTCTCGTCTCCACAG (SEQ ID NO: (HDR) 8) PB1151 GCAATTCCTCACGAGACCCGTCCTGAGGACATCG AcuI for EMX1 ATGTCACTGAAGCCTCCAATGACTAG (SEQ ID NO: (HDR) 9) PB1019 gatcctctagagtcgacctgAAACGGCAGAAGCTGGAGGA AcuI for EMX1 CTGAAGGGAAGGGCCTGAGT (SEQ ID NO: 10) (Base editing) PB1080 GCAATTCCTCACGAGACCCGTCCTGGTTCAGTTTA AcuI for SPRTN- ACGACCTGAAGCAATTCTTCTGGGG (SEQ ID NO: STOP 11) PB1149 GCAATTCCTCACGAGACCCGTCCTGTGTGTTCACT AcuI for HBB AGCAACTGAAGCCTCAAACAGACAC (SEQ ID NO: (HDR) 12) PB1211 GCAATTCCTCACGAGACCCGTCCTGGAGGAGGAG AcuI for TCOF1 GCCCCTCTGAAGGCAGGGACACGAAG (SEQ ID (Base editing) NO: 13) oligo plate GAT CCT CTA GAG TCG ACC TGC CAA ATT ATA BRCA1 C64Y TAC CTT TTG GCT GAA GTT ATA TCA TTC TTA AcuI (SEQ ID NO: 14) oligo plate GAT CCT CTA GAG TCG ACC TGT CTT CAC TGC BRCA1 E638K TAG AAC AAC TCT GAA GAT CAA TTT GCA ATT AcuI (SEQ ID NO: 15) oligo plate GAT CCT CTA GAG TCG ACC TGA TAT TGC TTG BRCA1 E1033K AGC TGG CTT CCT GAA GTT TAA AAA CAT TTT AcuI (SEQ ID NO: 16) oligo plate GAT CCT CTA GAG TCG ACC TGG GTT CAG CTT BRCA1 E575K TCG TTT TGA ACT GAA GAG CAG ATT CTT TTT AcuI (SEQ ID NO: 17) oligo plate GAT CCT CTA GAG TCG ACC TGT CCT CTA GCA BRCA1 V990I GAT TTT TCT TCT GAA GAC ATT TAG TTT TAA AcuI (SEQ ID NO: 18) oligo plate GAT CCT CTA GAG TCG ACC TGG GAA AGA ATG BRCA1 T922I AGT CTA ATA TCT GAA GCA AGC CTG TAC AGA AcuI (SEQ ID NO: 19) oligo plate GAT CCT CTA GAG TCG ACC TGC ATC ATT ACC BRCA1 D67N AAA TTA TAT ACT GAA GCC TTT TGG TTA TAT AcuI (SEQ ID NO: 20) oligo plate GAT CCT CTA GAG TCG ACC TGG AGG GAG GGA BRCA1 E1754K GCT TTA CCT TCT GAA GTC TGT CCT GGG ATT AcuI (SEQ ID NO: 21) oligo plate GAT CCT CTA GAG TCG ACC TGG AAG AAA ATA BRCA1 S1363L ATC AAG AAG ACT GAA GGC AAA GCA TGG ATT AcuI (SEQ ID NO: 22) oligo plate GAT CCT CTA GAG TCG ACC TGG CAG TGA TTT BRCA1 Q1779* TAC ATC TAA ACT GAA GTG TCC ATT TTA GAT AcuI (SEQ ID NO: 23) oligo plate GAT CCT CTA GAG TCG ACC TGG ATG GAG AAG BRCA2 R2842C ACA TCA TCT GCT GAA GGA TTA TAC ATA TTT AcuI (SEQ ID NO: 24) oligo plate GAT CCT CTA GAG TCG ACC TGT GAA TCT TTT BRCA2 R2973H TCT TTT TTT GCT GAA GAA TAG CTT ACA ATA AcuI (SEQ ID NO: 25) oligo plate GAT CCT CTA GAG TCG ACC TGC TGA GTA TTT BRCA2 S2998F GGC GTC CAT CCT GAA GAT CAG ATT TAT ATT AcuI (SEQ ID NO: 26) oligo plate GAT CCT CTA GAG TCG ACC TGC AAA TTT TTA BRCA2 S3070F GAT CCA GAC TCT GAA GTC AGC CAT CTT GTT AcuI (SEQ ID NO: 27) oligo plate GAT CCT CTA GAG TCG ACC TGA GTG CAA ATT BRCA2 E2772K AAT TTA CCT TCT GAA GTA ACA TAA GAG ATT AcuI (SEQ ID NO: 28) oligo plate GAT CCT CTA GAG TCG ACC TGG GAA TAT TTG BRCA2 T1707I ATG GTC AAC CCT GAA GAG AAA GAA TAA ATA AcuI (SEQ ID NO: 29) oligo plate GAT CCT CTA GAG TCG ACC TGA TCT TGT TCT BRCA2 V3079I GAG GTG GAC CCT GAA GTA ATA GGA TTT GTC AcuI (SEQ ID NO: 30) oligo plate GAT CCT CTA GAG TCG ACC TGT AGG AAG GCC BRCA2 Q2960* ATG GAA TCT GCT GAA GCT GAA CAA AAG GAA AcuI (SEQ ID NO: 31) oligo plate GAT CCT CTA GAG TCG ACC TGA ACT GAA GCC BRCA2 T544I TCT GAA AGT GCT GAA GAC TGG AAA TAC ATA AcuI (SEQ ID NO: 32) oligo plate GAT CCT CTA GAG TCG ACC TGT TTA CCA TCA BRCA2 R2896C CGT GCA CTA ACT GAA GCA AGA CAG CAA GTT AcuI (SEQ ID NO: 33) oligo plate GAT CCT CTA GAG TCG ACC TGT GGA AGC TGG BRCA2 V572I CCA GCC ACC ACT GAA GCC ACA CAG AAT TCT AcuI (SEQ ID NO: 34) oligo plate GAT CCT CTA GAG TCG ACC TGT TGC CTC TAG BRCA2 V778I AAA TCA TGA CCT GAA GTA GGT TTG ACA GAA AcuI (SEQ ID NO: 35) oligo plate GAT CCT CTA GAG TCG ACC TGT TTC TCT TAT BRCA2 V2102I CAA CAC GAG GCT GAA GAA GTA TTT TTG ATA AcuI (SEQ ID NO: 36) AA1 GAT CCT CTA GAG TCG ACC TGC AAA CGA CGA For adaptor library GCG TGA CAC CCT GAA GAC GAT GCC TGT AGC testing (SEQ ID NO: 37) AA2 GAT CCT CTA GAG TCG ACC TGT CGT TGG GAA For adaptor library CCG GAG CTG ACT GAA GAT GAA GCC ATA CCA testing (SEQ ID NO: 38) AC1 GAT CCT CTA GAG TCG ACC TGG AGC TGA ATG For adaptor library AAG CCA TAC CCT GAA GAA ACG ACG AGC GTG testing (SEQ ID NO: 39) AC2 GAT CCT CTA GAG TCG ACC TGG CTG AAT GAA For adaptor library GCC ATA CCA ACT GAA GAC GAC GAG CGT GAC testing (SEQ ID NO: 40) AG1 GAT CCT CTA GAG TCG ACC TGG AAC CGG AGC For adaptor library TGA ATG AAG CCT GAA GCA TAC CAA ACG ACG testing (SEQ ID NO: 41) AG2 GAT CCT CTA GAG TCG ACC TGT ACC AAA CGA For adaptor library CGA GCG TGA CCT GAA GAC CAC GAT GCC TGT testing (SEQ ID NO: 42) AT1 GAT CCT CTA GAG TCG ACC TGT GAA GCC ATA For adaptor library CCA AAC GAC GCT GAA GAG CGT GAC ACC ACG testing (SEQ ID NO: 43) AT2 GAT CCT CTA GAG TCG ACC TGA AAC GAC GAG For adaptor library CGT GAC ACC ACT GAA GCG ATG CCT GTA GCA testing (SEQ ID NO: 44) CA1 GAT CCT CTA GAG TCG ACC TGG ATC GTT GGG For adaptor library AAC CGG AGC TCT GAA GGA ATG AAG CCA TAC testing (SEQ ID NO: 45) CA2 GAT CCT CTA GAG TCG ACC TGA GCT GAA TGA For adaptor library AGC CAT ACC ACT GAA GAA CGA CGA GCG TGA testing (SEQ ID NO: 46) CC1 GAT CCT CTA GAG TCG ACC TGC TGA ATG AAG For adaptor library CCA TAC CAA ACT GAA GCG ACG AGC GTG ACA testing (SEQ ID NO: 47) CC2 GAT CCT CTA GAG TCG ACC TGA GCC ATA CCA For adaptor library AAC GAC GAG CCT GAA GGT GAC ACC ACG ATG testing (SEQ ID NO: 48) CG1 GAT CCT CTA GAG TCG ACC TGA CCG GAG CTG For adaptor library AAT GAA GCC ACT GAA GTA CCA AAC GAC GAG testing (SEQ ID NO: 49) CG2 GAT CCT CTA GAG TCG ACC TGA ATG AAG CCA For adaptor library TAC CAA ACG ACT GAA GCG AGC GTG ACA CCA testing (SEQ ID NO: 50) CT1 GAT CCT CTA GAG TCG ACC TGG CCA TAC CAA For adaptor library ACG ACG AGC GCT GAA GTG ACA CCA CGA TGC testing (SEQ ID NO: 51) CT2 GAT CCT CTA GAG TCG ACC TGT CAT GTA ACT For adaptor library CGC CTT GAT CCT GAA GGT TGG GAA CCG GAG testing (SEQ ID NO: 52) GA1 GAT CCT CTA GAG TCG ACC TGG GAG CTG AAT For adaptor library GAA GCC ATA CCT GAA GCA AAC GAC GAG CGT testing (SEQ ID NO: 53) GA2 GAT CCT CTA GAG TCG ACC TGG GAA CCG GAG For adaptor library CTG AAT GAA GCT GAA GCC ATA CCA AAC GAC testing (SEQ ID NO: 54) GC1 GAT CCT CTA GAG TCG ACC TGA ACC GGA GCT For adaptor library GAA TGA AGC CCT GAA GAT ACC AAA CGA CGA testing (SEQ ID NO: 55) GC2 GAT CCT CTA GAG TCG ACC TGA AGC CAT ACC For adaptor library AAA CGA CGA GCT GAA GCG TGA CAC CAC GAT testing (SEQ ID NO: 56) GG1 GAT CCT CTA GAG TCG ACC TGA CGA CGA GCG For adaptor library TGA CAC CAC GCT GAA GAT GCC TGT AGC AAT testing (SEQ ID NO: 57) GG2 GAT CCT CTA GAG TCG ACC TGA GCA ATG GCA For adaptor library ACA ACG TTG CCT GAA GGC AAA CTA TTA ACT testing (SEQ ID NO: 58) GT1 GAT CCT CTA GAG TCG ACC TGC CGG AGC TGA For adaptor library ATG AAG CCA TCT GAA GAC CAA ACG ACG AGC testing (SEQ ID NO: 59) GT2 GAT CCT CTA GAG TCG ACC TGC ATA CCA AAC For adaptor library GAC GAG CGT GCT GAA GAC ACC ACG ATG CCT testing (SEQ ID NO: 60) TA1 GAT CCT CTA GAG TCG ACC TGC TTG ATC GTT For adaptor library GGG AAC CGG ACT GAA GGC TGA ATG AAG CCA testing (SEQ ID NO: 61) TA2 GAT CCT CTA GAG TCG ACC TGA TAC CAA ACG For adaptor library ACG AGC GTG ACT GAA GCA CCA CGA TGC CTG testing (SEQ ID NO: 62) TC1 GAT CCT CTA GAG TCG ACC TGc cgc ttt ttt For adaptor library (PB1040) gca caa cat gCT GAA Ggg gga tca tgt aac testing (SEQ ID NO: 63) TC2 GAT CCT CTA GAG TCG ACC TGC GTT GCG CAA For adaptor library ACT ATT AAC TCT GAA GGG CGA ACT ACT TAC testing (SEQ ID NO: 64) TG1 GAT CCT CTA GAG TCG ACC TGC GGA GCT GAA For adaptor library TGA AGC CAT ACT GAA GCC AAA CGA CGA GCG testing (SEQ ID NO: 65) TG2 gat cct cta gag tcg acc tgc cat acc aaa For adaptor library (PB1070) cga cga gcg tCT GAA Gga cac cac gat gcc testing (SEQ ID NO: 66) TT1 GAT CCT CTA GAG TCG ACC TGT GAC ACC ACG For adaptor library ATG CCT GTA GCT GAA GCA ATG GCA ACA ACG testing (SEQ ID NO: 67) TT2 GAT CCT CTA GAG TCG ACC TGG CCT GTA GCA For adaptor library ATG GCA ACA ACT GAA GCG TTG CGC AAA CTA testing (SEQ ID NO: 68) PB1477 GCAATTCCTCACGAGACCCGTCCTGACCTGAGTT FANCD2 AcuI CTTTCCCTGAAGCCACATCAGCGTGC (SEQ ID NO: 69) PB1257 GATCCTCTAGAGTCGACCTGCCGCAGAGCTGAGA SMARCAL1 AcuI AGTTATCTGAAGTGGCAGAACAGCAT (SEQ ID NO: 70) PB1264 gatcctctagagtcgacctgGTTTTCATTTCAGGGAAGAAC PIK3R1 TGAAGGTGAATGAAAAACT (SEQ ID NO: 71) signatures PB1265 gatcctctagagtcgacctgTCTCGTACCAAAAAGGTCCCC PIK3R1 TGAAGGTCTGCTGTATCTC (SEQ ID NO: 72) signatures PB1266 gatcctctagagtcgacctgATCTCGTACCAAAAAGGTCCC PIK3R1 TGAAGCGTCTGCTGTATCT (SEQ ID NO: 73) signatures PB1010 gatcctctagagtcgacctgTTTTCATTTCAGGGAAGAAGC PIK3R1 TGAAGTGAATGAAAAACTT (SEQ ID NO: 74) signatures PB1433 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC AA-Oligo to test TGAAGaactggcgaactacAA (SEQ ID NO: 75) dinucleotide capture efficiency (DTECT) PB1434 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC AC-Oligo to test TGAAGaactggcgaactacAC (SEQ ID NO: 76) dinucleotide capture efficiency (DTECT) PB1435 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC AG-Oligo to test TGAAGaactggcgaactacAG (SEQ ID NO: 77) dinucleotide capture efficiency (DTECT) PB1436 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC AT-Oligo to test TGAAGaactggcgaactacAT (SEQ ID NO: 78) dinucleotide capture efficiency (DTECT) PB1437 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC CA-Oligo to test TGAAGaactggcgaactacCA (SEQ ID NO: 79) dinucleotide capture efficiency (DTECT) PB1438 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC CC-Oligo to test TGAAGaactggcgaactacCC (SEQ ID NO: 80) dinucleotide capture efficiency (DTECT) PB1439 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC CG-Oligo to test TGAAGaactggcgaactacCG (SEQ ID NO: 81) dinucleotide capture efficiency (DTECT) PB1440 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC CT-Oligo to test TGAAGaactggcgaactacCT (SEQ ID NO: 82) dinucleotide capture efficiency (DTECT) PB1441 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC GA-Oligo to test TGAAGaactggcgaactacGA (SEQ ID NO: 83) dinucleotide capture efficiency (DTECT) PB1442 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC GC-Oligo to test TGAAGaactggcgaactacGC (SEQ ID NO: 84) dinucleotide capture efficiency (DTECT) PB1443 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC GG-Oligo to test TGAAGaactggcgaactacGG (SEQ ID NO: 85) dinucleotide capture efficiency (DTECT) PB1444 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC GT-Oligo to test TGAAGaactggcgaactacGT (SEQ ID NO: 86) dinucleotide capture efficiency (DTECT) PB1445 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC TA-Oligo to test TGAAGaactggcgaactacTA (SEQ ID NO: 87) dinucleotide capture efficiency (DTECT) PB1446 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC TC-Oligo to test TGAAGaactggcgaactacTC (SEQ ID NO: 88) dinucleotide capture efficiency (DTECT) PB1447 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC TG-Oligo to test TGAAGaactggcgaactacTG (SEQ ID NO: 89) dinucleotide capture efficiency (DTECT) PB1448 GCAATTCCTCACGAGACCCGTCCTGtgcgcaaactattC TT-Oligo to test TGAAGaactggcgaactacTT (SEQ ID NO: 90) dinucleotide capture efficiency (DTECT) PB1449 gtagttcgccagttCTTCAGaatagtttgcgcaCAGGACGGGT Complementary CTCGTGAGGAATTGC (SEQ ID NO: 91) 5′-phosphorylated oligo PB1321 GCAATTCCTCACGAGACCCGTCCTGGTGGCTCCA mouse Pik3ca TAGGAACTGAAGGTCTTTCTCTTGTT (SEQ ID NO: (545) AcuI 92) PB1380 GCAATTCCTCACGAGACCCGTCCTGTTATATACCT BRCA1 Cys64Tyr TTTGGCTGAAGTTATATCATTCTTA (SEQ ID NO: AcuI 93) PB1381 GCAATTCCTCACGAGACCCGTCCTGACTGCTAGA BRCA1 ACAACTCTGAAGATCAATTTGCAATT (SEQ ID NO: Glu638Lys AcuI 94) PB1382 GCAATTCCTCACGAGACCCGTCCTGGCTTGAGCT BRCA1 GGCTTCCTGAAGTTTAAAAACATTTT (SEQ ID NO: Glu1033Lys AcuI 95) PB1383 GCAATTCCTCACGAGACCCGTCCTGAGCTTTCGTT BRCA1 TTGAACTGAAGAGCAGATTCTTTTT (SEQ ID NO: Glu575Lys AcuI 96) PB1386 GCAATTCCTCACGAGACCCGTCCTGTAGCAGATTT BRCA1 Va1990Ile TTCTTCTGAAGACATTTAGTTTTAA (SEQ ID NO: AcuI 97) PB1388 GCAATTCCTCACGAGACCCGTCCTGGAATGAGTC BRCA1 Thr922Ile TAATATCTGAAGCAAGCCTGTACAGA (SEQ ID NO: AcuI 98) PB1389 GCAATTCCTCACGAGACCCGTCCTGTTACCAAATT BRCA1 Asp67Asn ATATACTGAAGCCTTTTGGTTATAT (SEQ ID NO: AcuI 99) PB1390 GCAATTCCTCACGAGACCCGTCCTGAGGGAGCTT BRCA1 TACCTTCTGAAGTCTGTCCTGGGATT (SEQ ID NO: Glu1754Lys AcuI 100) PB1393 GCAATTCCTCACGAGACCCGTCCTGAAATAATCAA BRCA1 GAAGACTGAAGGCAAAGCATGGATT (SEQ ID NO: Ser1363Leu AcuI 101) PB1394 GCAATTCCTCACGAGACCCGTCCTGGATTTTACAT BRCA1 CTAAACTGAAGTGTCCATTTTAGAT (SEQ ID NO: Gln1779Ter AcuI 102) PB1396 GCAATTCCTCACGAGACCCGTCCTGAGAAGACAT BRCA2 CATCTGCTGAAGGATTATACATATTT (SEQ ID NO: Arg2842Cys AcuI 103) PB1397 GCAATTCCTCACGAGACCCGTCCTGCTTTTTCTTT BRCA2 TTTTGCTGAAGAATAGCTTACAATA (SEQ ID NO: Arg2973His AcuI 104) PB1398 GCAATTCCTCACGAGACCCGTCCTGTATTTGGCG BRCA2 TCCATCCTGAAGATCAGATTTATATT (SEQ ID NO: Ser2998Phe AcuI 105) PB1399 GCAATTCCTCACGAGACCCGTCCTGTTTTAGATCC BRCA2 AGACTCTGAAGTCAGCCATCTTGTT (SEQ ID NO: Ser3070Phe AcuI 106) PB1400 GCAATTCCTCACGAGACCCGTCCTGAAATTAATTT BRCA2 ACCTTCTGAAGTAACATAAGAGATT (SEQ ID NO: Glu2772Lys AcuI 107) PB1401 GCAATTCCTCACGAGACCCGTCCTGATTTGATGGT BRCA2 CAACCCTGAAGAGAAAGAATAAATA (SEQ ID NO: Thr17071Ie AcuI 108) PB1402 GCAATTCCTCACGAGACCCGTCCTGGTTCTGAGG BRCA2 TGGACCCTGAAGTAATAGGATTTGTC (SEQ ID NO: Va13079Ile AcuI 109) PB1403 GCAATTCCTCACGAGACCCGTCCTGAGGCCATGG BRCA2 AATCTGCTGAAGCTGAACAAAAGGAA (SEQ ID NO: Gln2960Ter AcuI 110) PB1405 GCAATTCCTCACGAGACCCGTCCTGAAGCCTCTG BRCA2 Thr544Ile AAAGTGCTGAAGACTGGAAATACATA (SEQ ID NO: AcuI 111) PB1406 GCAATTCCTCACGAGACCCGTCCTGCTTATCAACA BRCA2 CGAGGCTGAAGAAGTATTTTTGATA (SEQ ID NO: Va12102Ile AcuI 112) PB1407 GCAATTCCTCACGAGACCCGTCCTGCATCACGTG BRCA2 CACTAACTGAAGCAAGACAGCAAGTT (SEQ ID NO: Arg2896Cys AcuI 113) PB1408 GCAATTCCTCACGAGACCCGTCCTGGCTGGCCAG BRCA2 Val572Ile CCACCACTGAAGCCACACAGAATTCT (SEQ ID NO: AcuI 114) PB1409 GCAATTCCTCACGAGACCCGTCCTGTCTAGAAATC BRCA2 Val778Ile ATGACCTGAAGTAGGTTTGACAGAA (SEQ ID NO: AcuI 115) PB1509 GCAATTCCTCACGAGACCCGTCCTGGCATTTTCTG Bard1 S563F AcuI CTGCTCTGAAGGTGAAGAAAGCCCA (SEQ ID NO: 116) PB1513 GCAATTCCTCACGAGACCCGTCCTGgagcggatagag Brca1 S1598F acaCTGAAGtatccatggtggtg (SEQ ID NO: 117) AcuI PB1483 GCAATTCCTCACGAGACCCGTCCTGTGTGCGAGT NT5C2 R367Q TCAGGACTGAAGATCACCAAAAAAGT (SEQ ID NO: AcuI 118) PB1486 GCAATTCCTCACGAGACCCGTCCTGTTGGAGATC NT5C2 K359Q ACATTTCTGAAGTTGGGGACATTTTA (SEQ ID NO: AcuI 119) PB1493 GCAATTCCTCACGAGACCCGTCCTGTTTCAGGGA NT5C2 R238W AAACTGCTGAAGCCTTTGCTTCTGAG (SEQ ID NO: AcuI 120) PB1296 GCAATTCCTCACGAGACCCGTCCTGTGATACTGA BRCA2 AATTGACTGAAGTAGAAGCAGAAGAT (SEQ ID NO: dupAGAAGAT 121) AcuI PB1473 GCAATTCCTCACGAGACCCGTCCTGGCCAGCGAG TIMELESS AcuI AGATGGCTGAAGCAGAAAAGAAGACT (SEQ ID NO: 122) PB1476 GCAATTCCTCACGAGACCCGTCCTGGGGCAGCG SLX4 AcuI GGTGCCGCTGAAGGCGAGGACGCTGAC (SEQ ID NO: 123) PB1472 GCAATTCCTCACGAGACCCGTCCTGACGTTTACG FANCM AcuI GCCAGTCTGAAGTCTACCCATTCGTT (SEQ ID NO: 124) PB1427 GCAATTCCTCACGAGACCCGTCCTGGAAGCTCGG FANCF AcuI AAAAGCCTGAAGGATCCAGGTGCTGC (SEQ ID NO: 125) PB1430 GCAATTCCTCACGAGACCCGTCCTGATGTAGAATT AcuI Apc. 1529 AAGAACTGAAGTCATGCCTCCAGTT (SEQ ID NO: 126) PB1431 GCAATTCCTCACGAGACCCGTCCTGCCCGGGGCA AcuI Apc. 492 TTTCATCTGAAGCCCAGGAGCTAGGT (SEQ ID NO: 127) PB1318 GCAATTCCTCACGAGACCCGTCCTGTTGAGAGTC AcuI Apc. 1405 GCTCCACTGAAGTTGCCAGCTCTGTT (SEQ ID NO: 128) PB1332 GCAATTCCTCACGAGACCCGTCCTGAGCATTTGG AcuI Jak2 #1 TTTTGACTGAAGATTATGGTGTCTGT (SEQ ID NO: 129) PB1333 GCAATTCCTCACGAGACCCGTCCTGCTGGCTTTA AcuI Jak2 #2 CTTACTCTGAAGCTCCTCTCCACAGA (SEQ ID NO: 130) PB1460 GCAATTCCTCACGAGACCCGTCCTGAAGCATTTG AcuI Jak2 #3 GTTTTGCTGAAGAATTATGGTGTCTG (SEQ ID NO: 131) PB1461 GCAATTCCTCACGAGACCCGTCCTGGCTGGCTTT AcuI Jak2 #4 ACTTACCTGAAGTCTCCTCTCCACAG (SEQ ID NO: 132) PB1545 GCAATTCCTCACGAGACCCGTCCTGGAAGCAGGG AcuI HEK3 CTTCCTCTGAAGTTCCTCTGCCATCA (SEQ ID NO: 133) PB1301 GCAATTCCTCACGAGACCCGTCCTGGAAATTTGC AcuI TP53 R209fs GTGTGGCTGAAGAGTATTTGGATGAC (SEQ ID NO: delGA 134) PB1535 GCAATTCCTCACGAGACCCGTCCTGAACCAGACC AcuI TP53 delAG TCAGGCCTGAAGGGCTCATAGGGCAC (SEQ ID (PAM) NO: 135) Standard PCR primers Sequence (5′- ->3′) Notes Ampicillin CCA ATG CTT AAT CAG TGA GG (SEQ ID For adaptor library reverse NO: 136) testing AcuI-tagging AAT CGC TTG ATC ACA GAT GTA TGT A PCR BRCA1 C64Y oligo reverse (SEQ ID NO: 137) and BRCA1 D67N AcuI-tagging GAA GAC AAA ATA TTT GGG AAA ACC T PCR BRCA1 E638K oligo reverse (SEQ ID NO: 138) and BRCA1 E575K AcuI-tagging TCT CGT TAC TGG AAG TTA GCA CTC T PCR BRCA1 oligo reverse (SEQ ID NO: 139) E1033K and BRCA1 AcuI-tagging ATT TCA CCA TCA TCT AAC AGG TCA T V990I oligo reverse (SEQ ID NO: 140) PCR BRCA1 T922I AcuI-tagging CAC CTC CTG CAT TCA AAA GAT TC (SEQ PCR BRCA1 oligo reverse ID NO: 141) E1754K AcuI-tagging GCT GCT TCA CCT TAA ATA ACA AAA A PCR BRCA1 oligo reverse (SEQ ID NO: 142) S1363L AcuI-tagging AGG GAC ATA TGG GAA AAA GAG TTA G PCR BRCA1 oligo reverse (SEQ ID NO: 143) Q1779* AcuI-tagging TTA GAC CTG ATA TTT CTG TCC CTT G PCR BRCA2 oligo reverse (SEQ ID NO: 144) R2842C AcuI-tagging ACC TCT ACT ACC TAT GTG GCT TGT G PCR BRCA2 oligo reverse (SEQ ID NO: 145) R2973H AcuI-tagging GGT TTG TAC CGG TAG TTG TTG ATA C PCR BRCA2 oligo reverse (SEQ ID NO: 146) S2998F and BRCA2 Q2960* AcuI-tagging AAA TAG CCC TGT ACA ATG AAA AGT AGA PCR BRCA2 oligo reverse (SEQ ID NO: 147) S3070F and BRCA2 V30791 AcuI-tagging TCA TAT ACG GCA GTA TGG TTA AGG T PCR BRCA2 oligo reverse (SEQ ID NO: 148) E2772K AcuI-tagging GTG GCC CTA CCT CAA AAT TAT TAC T PCR BRCA2 T17071 oligo reverse (SEQ ID NO: 149) AcuI-tagging TAT CTA CCA TGT TTG AGT GAC CTG A PCR BRCA T544I oligo reverse (SEQ ID NO: 150) and BRCA2 V572I AcuI-tagging CTT CAT AAG TCA GTC TCA TCT GCA A PCR BRCA2 oligo reverse (SEQ ID NO: 151) V2102I AcuI-tagging GTA CAG GAG GGA CAA AAA TAA AAC A PCR BRCA2 oligo reverse (SEQ ID NO: 152) R2896C AcuI-tagging CCT TAA CTA GCT CTT TTG GGA CAA T PCR BRCA2 V778I oligo reverse (SEQ ID NO: 153) PB1150 GAAAATAGACCAATAGGCAGAGAGAGTC HBB PCR rev (SEQ ID NO: 154) PB1152 TGTCATTAAGAGAGAGACTTTTATTATTCC EMX1 PCR rev (SEQ ID NO: 155) PB1154 ATCCATCTACCTCAGTTTCCTATATCTATC JAK2 PCR rev (SEQ ID NO: 156) PB783 CCCTTTCCTGTAAAAACAATATAAAAA (SEQ PIK3R1 PCR rev ID NO: 157) PB764 TTCTGGAAAATGGATCTAAAGCTAATA (SEQ TCOF1 PCR RFLP ID NO: 158) for PB765 TCACAATTCGTAGTCCTACTTCTACCT (SEQ TCOF1 PCR RFLP ID NO: 159) rev TP226 ACGTTGATGGCAGTTGCAGGTC (SEQ ID JAK2 (HDR) for NO: 160) TP227 CTGACAGAGTTGCTAGACACTGGGTTG JAK2 (HDR) rev (SEQ ID NO: 161) PB969 AACGATCTTCAATATGCTTACCAAG (SEQ ID HBB PCR RFLP for NO: 162) PB970 CTTAACCATAGAAAAGAAGGGGAAA (SEQ ID HBB PCR RFLP rev NO: 163) PB327 GCCATCCCCTTCTGTGAATGTTAGAC (SEQ EMX1 PCR for ID NO: 164) PB328 GGAGATTGGAGACACGGAGAGCAG (SEQ ID EMX1 PCR rev NO: 165) PB1302 AACTGTGCAATAGTTAAACCCATTTAC (SEQ PCR TP53 (HDR) ID NO: 166) PB862 GTAGGTGTTCGGTAAATGTTAATGG (SEQ ID PCR FANCD2 NO: 167) PB863 AAGTCAAATCCCATACCCTACTCAT (SEQ ID PCR FANCD2 NO: 168) PB1334 TACTTGCTTTCAGTGTTGTGTTATAGG (SEQ PCR Jak2 (mouse) ID NO: 169) PB1335 ATTTGTTTACTGTAATCCTCATCCATC (SEQ PCR Jak2 (mouse) ID NO: 170) PB1319 GGAAAAGTTTATAGGTGTCCCTTCTAC (SEQ PCR Apc. 1405 ID NO: 171) PB1320 AGCAGGTGTACTTCTGTCAGCTC (SEQ ID PCR Apc. 1405 NO: 172) PB1432 AATATTCTGCAGACTGATATTCTGGTT (SEQ PCR Apc. 492 ID NO: 173) PB1428 CGTTACTTAATTTTGAAAAACCTCAAC (SEQ PCR FANCF ID NO: 174) PB1429 AGATTTGGGTTCTCTCTATAGCCATT (SEQ PCR FANCF ID NO: 175) PB745 GACTCCAGTCAAAAATTCTCCTAGTTA (SEQ PCR FANCM ID NO: 176) PB858 ATGTCTGCAGCTATAGTTAGGAAGC (SEQ ID PCR SLX4 NO: 177) PB859 ATCTCTCCCTGAGTTGATGAGAAG (SEQ ID PCR SLX4 NO: 178) PB764 TTCTGGAAAATGGATCTAAAGCTAATA (SEQ PCR TCOF1 ID NO: 179) PB765 TCACAATTCGTAGTCCTACTTCTACCT (SEQ PCR TCOF1 ID NO: 180) PB746 CTGTTTGTCCTAAACAAGATGTGAAT (SEQ PCR TIMELESS ID NO: 181) PB747 CATTGGAGCAAGTTAAAACTACAAAAT (SEQ PCR TIMELESS ID NO: 182) PB1297 CCTTAACCTCTTGATGTATGAGAAGAA (SEQ PCR BRCA2 ID NO: 183) dupAGAAGAT PB1298 AGTACATCTAAGAAATTGAGCATCCTT (SEQ PCR BRCA2 ID NO: 184) dupAGAAGAT PB590 GTGTGTGTGCAATTATAAAAGAAACTT (SEQ PCR SMARCAL1 ID NO: 185) PB591 GTCAGCATTAGATGAGCTACTGAGATT (SEQ PCR SMARCAL1 ID NO: 186) PB1322 CTGTTCTACTTGTTGGTGGTGATAATA (SEQ PCR mouse Pik3ca ID NO: 187) (545) PB1323 ATGGTAAGAAATATGGTTAACACCAAG (SEQ PCR mouse Pik3ca ID NO: 188) (545) PB1510 CTATTTTAGGTTACTGGGAACAGAATG (SEQ Oligos for Bard1 ID NO: 189) S563F genotyping PB1511 AAACTACATAACTACAACCCAATGCTT (SEQ Oligos for Bard1 ID NO: 190) S563F genotyping PB1514 GAACCCCATACCTGGGATCT (SEQ ID NO: Oligos for Brca1 191) S1598F genotyping PB1515 tcatacctcacaaggtgccta (SEQ ID NO: 192) Oligos for Brca1 S1598F genotyping PB1548 TTATCAGTTTTGGAGGATGTACATAAA (SEQ PCR HEK3 rev ID NO: 193) PB780 CTCCTTCCTCTTCCTACAGTACTCC (SEQ ID TP53 gDNA for NO: 194) (PAM) Illumina primers (NGS) Sequence (5′- ->3′) Notes Primers for amplifying AcuI-tagged amplicons SAM175 ACACTCTTTCCCTACACGACGCTCTTCCGATC Adaptor constant TTTCCTCACGAGACCCGTCCTG (SEQ ID NO: forward - Forward 195) primer used with all amplicons - binds AcuI-tagging primer sequence SAM176 AGACGTGTGCTCTTCCGATCTCTTGATCACAG NGS BRCA1 C64Y ATGTATGTA (SEQ ID NO: 196) AcuI SAM177 AGACGTGTGCTCTTCCGATCTCAAAATATTTG NGS BRCA1 E638K GGAAAACCT (SEQ ID NO: 197) AcuI SAM178 AGACGTGTGCTCTTCCGATCTTTACTGGAAGT NGS BRCA1 TAGCACTCT (SEQ ID NO: 198) E1033K AcuI SAM179 AGACGTGTGCTCTTCCGATCTCAAAATATTTG NGS BRCA1 E575K GGAAAACCT (SEQ ID NO: 199) AcuI SAM182 AGACGTGTGCTCTTCCGATCTTTACTGGAAGT NGS BRCA1 V990I TAGCACTCT (SEQ ID NO: 200) AcuI SAM184 AGACGTGTGCTCTTCCGATCTACCATCATCTA NGS BRCA1 T922I ACAGGTCAT (SEQ ID NO: 201) AcuI SAM185 AGACGTGTGCTCTTCCGATCTCTTGATCACAG NGS BRCA1 D67N ATGTATGTA (SEQ ID NO: 202) AcuI SAM186 AGACGTGTGCTCTTCCGATCTCTCCTGCATTC NGS BRCA1 AAAAGATTC (SEQ ID NO: 203) E1754K AcuI SAM189 AGACGTGTGCTCTTCCGATCTTTCACCTTAAA NGS BRCA1 TAACAAAAA (SEQ ID NO: 204) S1363L AcuI SAM190 AGACGTGTGCTCTTCCGATCTCATATGGGAAA NGS BRCA1 AAGAGTTAG (SEQ ID NO: 205) Q1779* AcuI SAM192 AGACGTGTGCTCTTCCGATCTCCTGATATTTC NGS BRCA2 TGTCCCTTG (SEQ ID NO: 206) R2842C AcuI SAM193 AGACGTGTGCTCTTCCGATCTTACTACCTATG NGS BRCA2 TGGCTTGTG (SEQ ID NO: 207) R2973H AcuI SAM194 AGACGTGTGCTCTTCCGATCTGTACCGGTAGT NGS BRCA2 TGTTGATAC (SEQ ID NO: 208) S2998F AcuI SAM195 AGACGTGTGCTCTTCCGATCTCCTGTACAATG NGS BRCA2 AAAAGTAGA (SEQ ID NO: 209) S3070F AcuI SAM196 AGACGTGTGCTCTTCCGATCTTACGGCAGTAT NGS BRCA2 GGTTAAGGT (SEQ ID NO: 210) E2772K AcuI SAM197 AGACGTGTGCTCTTCCGATCTCCTACCTCAAA NGS BRCA2 T17071 ATTATTACT (SEQ ID NO: 211) AcuI SAM198 AGACGTGTGCTCTTCCGATCTCCTGTACAATG NGS BRCA2 V30791 AAAAGTAGA (SEQ ID NO: 212) AcuI SAM199 AGACGTGTGCTCTTCCGATCTGTACCGGTAGT NGS BRCA2 TGTTGATAC (SEQ ID NO: 213) Q2960* AcuI SAM201 AGACGTGTGCTCTTCCGATCTACCATGTTTGA NGS BRCA2 T544I GTGACCTGA (SEQ ID NO: 214) AcuI SAM202 AGACGTGTGCTCTTCCGATCTTAAGTCAGTCT NGS BRCA2 V2102I CATCTGCAA (SEQ ID NO: 215) AcuI SAM203 AGACGTGTGCTCTTCCGATCTGGAGGGACAA NGS BRCA2 AAATAAAACA (SEQ ID NO: 216) R2896C AcuI SAM204 AGACGTGTGCTCTTCCGATCTACCATGTTTGA NGS BRCA2 V572I GTGACCTGA (SEQ ID NO: 217) AcuI SAM205 AGACGTGTGCTCTTCCGATCTACTAGCTCTTT NGS BRCA2 V778I TGGGACAAT (SEQ ID NO: 218) AcuI Primers for indexing the above amplicons SAM113 caagcagaagacggcatacgagatTGCCTCTTgtgactgga N711 gttcagacgtgtgctcttccgatct (SEQ ID NO: 219) SAM64 aatgatacggcgaccaccgagatctacacACTGCATAacact S506 ctttccctacacgacg (SEQ ID NO: 220) TP370 acactctttccctacacgacgctcttccgatctGTTTAAACAGT BRCA2_NGS_F GGAATTCTAGAGTCA (SEQ ID NO: 221) TP371 agacgtgtgctcttccgatctTTTTTGCAGCTGTGTCATC BRCA2_NGS_R C (SEQ ID NO: 222) TP372 acactctttccctacacgacgctcttccgatctGCCCCTCCTC TP53_NGS_F AGCATCTTAT (SEQ ID NO: 223) TP373 agacgtgtgctcttccgatctCTTAACCCCTCCTCCCAG TP53_NGS_R AG (SEQ ID NO: 224) ssODNs: Targeted Sequence (5′- ->3′) gene TTCCTTAGTCTTTCTTTGAAGCAGCAAGTATGATGAGCAAGCTTTCTCA JAK2 CAAGCATTTGGTTTTAAATTATGGAGTATGTGTgtttaaacCTGTGGAGACG AGAGTAAGTAAAACTACAGGCTTTCTAATGCCTTTCTCAGAGCATCTGT TTTTGTTTATATAGAAAATTCAGTTTCAGGATCA (SEQ ID NO: 225) AAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACGAAGCA EMX1 GGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAgtttaaacGGG TGGGCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCC AGGCCCCTGCGTGGGCCCAAGCTGGACTCTGGCCACTCCC (SEQ ID NO: 226) TACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACA HBB CAATGGTGCATCTGACTCCTGTCGAGAAGTCTGCCGTTACTGCCCTGT GGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGG (SEQ ID NO: 227) TCTTAGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATT TP53 TGCGTGTGGAGTATTTGGATGACAAACACTTTTCGTCATAGTGTGGTTG R209fs*6 TGCCCTATGAGCCGCCTGAGGTCTGGTTTGCAACTGGGGTCTCTGGG AGGAGGGGTTAAGGGTGGTTGT (SEQ ID NO: 228) TTGTTTAAACAGTGGAATTCTAGAGTCACACTTCCTAAAATATGCATTTT BRCA2 TGTTTTCACTTTTAGATATGATACTGAAATTGATAGAAGCAGAAGATAG dupAGA AAGATCGGCTATAAAAAAGATAATGGAAAGGGATGACACAGCTGCAAA AGAT AACACTTGTTCTCTGTGTTTCTGACATAAT (SEQ ID NO: 229) Libray of adaptors: Oligo Sequence (5′- ->3′) Notes PB984 CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCT Oligo corresponds to TCTAAgaattcgagctcggtacccg (SEQ ID NO: 230) the constant strand of the adaptor PB985 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGGG (SEQ ID NO: the variable strand of 231) the adaptor. It contains a 3′ GG, expected to ligate to CC PB986 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGAG (SEQ ID NO: 232) the variable strand of the adaptor. It contains a 3′ AG, expected to ligate to CT PB987 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGAA (SEQ ID NO: 233) the variable strand of the adaptor. It contains a 3′ AA, expected to ligate to TT PB988 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGTG (SEQ ID NO: 234) the variable strand of the adaptor. It contains a 3′ TG, expected to ligate to CA PB989 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGTA (SEQ ID NO: 235) the variable strand of the adaptor. It contains a 3′ TA, expected to ligate to TA PB990 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGCG (SEQ ID NO: 236) the variable strand of the adaptor. It contains a 3′ CG, expected to ligate to CG PB991 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGCA (SEQ ID NO: 237) the variable strand of the adaptor. It contains a 3′ CA, expected to ligate to TG PB992 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG O1igo corresponds to CTTCTTACCCGTGCCCCAGCT (SEQ ID NO: 238) the variable strand of the adaptor. It contains a 3′ CT, expected to ligate to AG PB993 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGGA (SEQ ID NO: 239) the variable strand of the adaptor. It contains a 3′ GA, expected to ligate to TC PB1000 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGAC (SEQ ID NO: 240) the variable strand of the adaptor. It contains a 3′ AC, expected to ligate to GT PB1001 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGAT (SEQ ID NO: 241) the variable strand of the adaptor. It contains a 3′ AT, expected to ligate to AT PB1002 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGCC (SEQ ID NO: 242) the variable strand of the adaptor. It contains a 3′ CC, expected to ligate to GG PB1003 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGGC (SEQ ID NO: 243) the variable strand of the adaptor. It contains a 3′ GC, expected to ligate to GC PB1004 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGGT (SEQ ID NO: 244) the variable strand of the adaptor. It contains a 3′ GT, expected to ligate to AC PB1005 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGTC (SEQ ID NO: 245) the variable strand of the adaptor. It contains a 3′ TC, expected to ligate to GA PB1006 cgggtaccgagctcgaattcTTAGAAGAGAGACAGAATG Oligo corresponds to CTTCTTACCCGTGCCCCAGTT (SEQ ID NO: 246) the variable strand of the adaptor. It contains a 3′ TT, expected to ligate to AA Oligos (sgRNAs cloning): Oligo Sequence (5′- ->3′) Target/Notes oligo plate CAC CGT ACA TAA AGG ACA CTG TGA BRCA1 C64Y for (SEQ ID NO: 247) oligo plate CAC CGC AAT TCA GTA CAA TTA GGT BRCA1 E638K for (SEQ ID NO: 248) oligo plate CAC CGA TTT TCT CTA ATG TTA TTA BRCA1 E1033K for (SEQ ID NO: 249) oligo plate CAC CGT TTT TCG AGT GAT TCT ATT BRCA1 E575K for (SEQ ID NO: 250) oligo plate CAC CGT TTT AAC AAA TGA CTT GAT BRCA1 V990I for (SEQ ID NO: 251) oligo plate CAC CGA GAC AGT TAA TAT CAC TGC BRCA1 T922I for (SEQ ID NO: 252) oligo plate CAC CGT TAT ATC ATT CTT ACA TAA BRCA1 D67N for (SEQ ID NO: 253) oligo plate CAC CGG GGA TTC TCT TGC TCG CTT BRCA1 E1754K for (SEQ ID NO: 254) oligo plate CAC CGT GGA TTC AAA CTT AGG TAT BRCA1 51363L for (SEQ ID NO: 255) oligo plate CAC CGT TAG ATC AAC TGG AAT GGA BRCA1 Q1779* for (SEQ ID NO: 256) oligo plate CAC CGA TAT TTC GCA ATG AAA GAG BRCA2 R2842C for (SEQ ID NO: 257) oligo plate CAC CGA CAA TAC GCA ACT TCC ACA BRCA2 R2973H for (SEQ ID NO: 258) oligo plate CAC CGT ATA TTC TCT GTT AAC AGA BRCA2 S2998F for (SEQ ID NO: 259) oligo plate CAC CGG TTC TGA GGT GGA CCT AAT BRCA2 S3070F for (SEQ ID NO: 260) oligo plate CAC CGG AGA TTC TGG GGC TTC AAG BRCA2 E2772K for (SEQ ID NO: 261) oligo plate CAC CGT AAA TAC TGC AGA TTA TGT BRCA2 T1707I for (SEQ ID NO: 262) oligo plate CAC CGA GAA ACG ACA AAT CCT ATT BRCA2 V3079I for (SEQ ID NO: 263) oligo plate CAC CGA AGG AAC AAG GTT TAT CAA BRCA2 Q2960* for (SEQ ID NO: 264) oligo plate CAC CGC ATA CTG TTT GCT CAC AGA BRCA2 T544I for (SEQ ID NO: 265) oligo plate CAC CGG CTA CAG AAT TCT GTG TGG BRCA2 V572I for (SEQ ID NO: 266) oligo plate CAC CGA CAG AAC ATC CTT GGA AGT BRCA2 V778I for (SEQ ID NO: 267) oligo plate AAA CTC ACA GTG TCC TTT ATG TAC BRCA1 C64Y rev (SEQ ID NO: 268) oligo plate AAA CAC CTA ATT GTA CTG AAT TGC BRCA1 E638K rev (SEQ ID NO: 269) oligo plate AAA CTA ATA ACA TTA GAG AAA ATC BRCA1 E1033K rev (SEQ ID NO: 270) oligo plate AAA CAA TAG AAT CAC TCG AAA AAC BRCA1 E575K rev (SEQ ID NO: 271) oligo plate AAA CAT CAA GTC ATT TGT TAA AAC BRCA1 V990I rev (SEQ ID NO: 272) oligo plate AAA CGC AGT GAT ATT AAC TGT CTC BRCA1 T922I rev (SEQ ID NO: 273) oligo plate AAA CTT ATG TAA GAA TGA TAT AAC BRCA1 D67N rev (SEQ ID NO: 274) oligo plate AAA CAA GCG AGC AAG AGA ATC CCC BRCA1 E1754K rev (SEQ ID NO: 275) oligo plate AAA CAT ACC TAA GTT TGA ATC CAC BRCA1 S1363L rev (SEQ ID NO: 276) oligo plate AAA CTC CAT TCC AGT TGA TCT AAC BRCA1 Q1779* rev (SEQ ID NO: 277) oligo plate AAA CCT CTT TCA TTG CGA AAT ATC BRCA2 R2842C rev (SEQ ID NO: 278) oligo plate AAA CTG TGG AAG TTG CGT ATT GTC BRCA2 R2973H rev (SEQ ID NO: 279) oligo plate AAA CTC TGT TAA CAG AGA ATA TAC BRCA2 S2998F rev (SEQ ID NO: 280) oligo plate AAA CAT TAG GTC CAC CTC AGA ACC BRCA2 S3070F rev (SEQ ID NO: 281) oligo plate AAA CCT TGA AGC CCC AGA ATC TCC BRCA2 E2772K rev (SEQ ID NO: 282) oligo plate AAA CAC ATA ATC TGC AGT ATT TAC BRCA2 T17071 rev (SEQ ID NO: 283) oligo plate AAA CAA TAG GAT TTG TCG TTT CTC BRCA2 V30791 rev (SEQ ID NO: 284) oligo plate AAA CTT GAT AAA CCT TGT TCC TTC BRCA2 Q2960* rev (SEQ ID NO: 285) oligo plate AAA CTC TGT GAG CAA ACA GTA TGC BRCA2 T544I rev (SEQ ID NO: 286) oligo plate AAA CCC ACA CAG AAT TCT GTA GCC BRCA2 V572I rev (SEQ ID NO: 287) oligo plate AAA CAC TTC CAA GGA TGT TCT GTC BRCA2 V778I rev (SEQ ID NO: 288) PB776 CACCGAACTTcGAGATACAGCAGAC (SEQ PIK3R1 R348* for ID NO: 289) PB777 AAACGTCTGCTGTATCTCgAAGTTC (SEQ PIK3R1 R348* rev ID NO: 290) PB551 CACCGGGCCAGCTGGAGGCCGTCG SPRTN Q60* for (SEQ ID NO: 291) PB552 AAACCGACGGCCTCCAGCTGGCCC (SEQ SPRTN Q60* rev ID NO: 292) PB756 CACCGAGCcAGGTGAGGCCTGGAGG TCOF1 Q290* for (SEQ ID NO: 293) PB757 AAACCCTCCAGGCCTCACCTgGCTC (SEQ TCOF1 Q290* rev ID NO: 294) TP212 CACCGAATTATGGAGTATGTGTCTG (SEQ JAK2 HDR for ID NO: 295) TP213 AAACCAGACACATACTCCATAATTC (SEQ JAK2 HDR rev ID NO: 296) PB963 CACCGATGGTGCATCTGACTCCTG (SEQ HBB E6V HDR for ID NO: 297) PB964 AAACCAGGAGTCAGATGCACCATC (SEQ HBB E6V HDR rev ID NO: 298) PB1017 CACCGAGTCCGAGCAGAAGAAGAA (SEQ EMX1 Base editing for ID NO: 299) PB1018 AAACTTCTTCTTCTGCTCGGACTC (SEQ EMX1 Base editing rev ID NO: 300) PB325 CACCGGTCACCTCCAATGACTAGGG EMX1 HDR for (SEQ ID NO: 301) PB326 AAACCCCTAGTCATTGGAGGTGACC EMX1 HDR rev (SEQ ID NO: 302) PB1299 CACCGCACTTTTCGACATAGTGTGG (SEQ TP53 R209fs*6 ID NO: 303) PB1300 AAACCCACACTATGTCGAAAAGTGC (SEQ TP53 R209fs*6 ID NO: 304) PB580 CACCGCAGCATCAGAGGACTAGCTC SMARCAL1 Q34* (SEQ ID NO: 305) PB581 AAACGAGCTAGTCCTCTGATGCTGC SMARCAL1 Q34* (SEQ ID NO: 306) PB838 CACCGATTCCcAGCACGCTGATGTG (SEQ FANCD2 Q223* for ID NO: 307) PB839 AAACCACATCAGCGTGCTgGGAATC (SEQ FANCD2 Q223* rev ID NO: 308) E12 CAC CGA TAC ATT TTG TCT AGA CGT BRCA2 V2102I for (SEQ ID NO: 309) H06 AAA CAC GTC TAG ACA AAA TGT ATC BRCA2 V2102I rev (SEQ ID NO: 310) PB1294 CACCGTTTCACTTTTAGATATGATA (SEQ BRCA2 dupAGAAGAT for ID NO: 311) PB1295 AAACTATCATATCTAAAAGTGAAAC (SEQ BRCA2 dupAGAAGAT rev ID NO: 312) PB738 CACCGAAGACTCGAGCCCTCCAGCG TIMELESS R267* for (SEQ ID NO: 313) PB739 AAACCGCTGGAGGGCTCGAGTCTTC TIMELESS R267* rev (SEQ ID NO: 314) PB834 CACCGCAGCcAGTCAGCGTCCTCGC SLX4 W879* for (SEQ ID NO: 315) PB835 AAACGCGAGGACGCTGACTgGCTGC SLX4 W879* rev (SEQ ID NO: 316) PB736 CACCGGTACAACGAATGGGTAGAAC FANCM Q572* for (SEQ ID NO: 317) PB737 AAACGTTCTACCCATTCGTTGTACC (SEQ FANCM Q572* rev ID NO: 318)

DOCUMENTS CITED

-   Allen, F., Crepaldi, L., Alsinet, C., Strong, A. J., Kleshchevnikov,     V., De Angeli, P., Palenikova, P., Khodak, A., Kiselev, V., Kosicki,     M., et al. (2018). Predicting the mutations generated by repair of     Cas9-induced double-strand breaks. Nature biotechnology. -   Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A.,     Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A.,     Raguram, A., et al. (2019). Search-and-replace genome editing     without double-strand breaks or donor DNA. Nature. -   Apostolou, P., and Fostira, F. (2013). Hereditary breast cancer: the     era of new susceptibility genes. Biomed Res Int 2013, 747318. -   Barbieri, E. M., Muir, P., Akhuetie-Oni, B. O., Yellman, C. M., and     Isaacs, F. J. (2017). Precise Editing at DNA Replication Forks     Enables Multiplex Genome Engineering in Eukaryotes. Cell 171,     1453-1467 e1413. -   Bath, A. J., Milsom, S. E., Gormley, N. A., and Halford, S. E.     (2002). Many type IIs restriction endonucleases interact with two     recognition sites before cleaving DNA. J Biol Chem 277, 4024-4033. -   Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K.,     Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K., et al.     (2014). Improved targeting of JAK2 leads to increased therapeutic     efficacy in myeloproliferative neoplasms. Blood 123, 2075-2083. -   Bhojwani, D., and Pui, C. H. (2013). Relapsed childhood acute     lymphoblastic leukaemia. Lancet Oncol 14, e205-217. -   Billing, D., Horiguchi, M., Wu-Baer, F., Taglialatela, A., Leuzzi,     G., Nanez, S. A., Jiang, W., Zha, S., Szabolcs, M., Lin, C. S., et     al. (2018). The BRCT Domains of the BRCA1 and BARD1 Tumor     Suppressors Differentially Regulate Homology-Directed Repair and     Stalled Fork Protection. Mol Cell 72, 127-139 e128. -   Billon, P., Bryant, E. E., Joseph, S. A., Nambiar, T. S.,     Hayward, S. B., Rothstein, R., and Ciccia, A. (2017).     CRISPR-Mediated Base Editing Enables Efficient Disruption of     Eukaryotic Genes through Induction of STOP Codons. Mol Cell 67,     1068-1079 e1064. -   Brinkman, E. K., Chen, T., Amendola, M., and van Steensel, B.     (2014). Easy quantitative assessment of genome editing by sequence     trace decomposition. Nucleic Acids Res 42, e168. -   Brinkman, E. K., Kousholt, A. N., Harmsen, T., Leemans, C., Chen,     T., Jonkers, J., and van Steensel, B. (2018). Easy quantification of     template-directed CRISPR/Cas9 editing. Nucleic Acids Res 46, e58. -   Canny, M. D., Moatti, N., Wan, L. C. K., Fradet-Turcotte, A.,     Krasner, D., Mateos-Gomez, P. A., Zimmermann, M., Orthwein, A.,     Juang, Y. C., Zhang, W., et al. (2018). Inhibition of 53BP1 favors     homology-dependent DNA repair and increases CRISPR-Cas9     genome-editing efficiency. Nat Biotechnol 36, 95-102. -   Ceccaldi, R., Sarangi, P., and D'Andrea, A. D. (2016). The Fanconi     anaemia pathway: new players and new functions. Nat Rev Mol Cell     Biol 17, 337-349. -   Chadwick, A. C., Wang, X., and Musunuru, K. (2017). In Vivo Base     Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as     a Therapeutic Alternative to Genome Editing. Arterioscler Thromb     Vasc Biol 37, 1741-1747. -   Clement, K., Rees, H., Canver, M. C., Gehrke, J. M., Farouni, R.,     Hsu, J. Y., Cole, M. A., Liu, D. R., Joung, J. K., Bauer, D. E., et     al. (2019). CRISPResso2 provides accurate and rapid genome editing     sequence analysis. Nature biotechnology 37, 224-226. -   Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N.,     Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013).     Multiplex genome engineering using CRISPR/Cas systems. Science 339,     819-823. -   Dieck, C. L., and Ferrando, A. A. (2019). Genetics and mechanisms of     NT5C2-driven chemotherapy resistance in relapsed ALL. Blood. -   Dow, L. E. (2015). Modeling Disease In Vivo With CRISPR/Cas9. Trends     Mol Med 21, 609-621. -   Fahim Farzadfard, T. K. L. (2018). Emerging applications for DNA     writers and molecular recorders. Science 361, 870-875. -   Findlay, G. M., Daza, R. M., Martin, B., Zhang, M. D., Leith, A. P.,     Gasperini, M., Janizek, J. D., Huang, X., Starita, L. M., and     Shendure, J. (2018). Accurate classification of BRCA1 variants with     saturation genome editing. Nature. -   Gao, X., Tao, Y., Lamas, V., Huang, M., Yeh, W. H., Pan, B., Hu, Y.     J., Hu, J. H., Thompson, D. B., Shu, Y., et al. (2018). Treatment of     autosomal dominant hearing loss by in vivo delivery of genome     editing agents. Nature 553, 217-221. -   Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S.,     Badran, A. H., Bryson, D. I., and Liu, D. R. (2017). Programmable     base editing of A*T to G*C in genomic DNA without DNA cleavage.     Nature. -   Germini, D., Tsfasman, T., Zakharova, V. V., Sjakste, N., Lipinski,     M., and Vassetzky, Y. (2018). A Comparison of Techniques to Evaluate     the Effectiveness of Genome Editing. Trends Biotechnol 36, 147-159. -   Guo, X., Chavez, A., Tung, A., Chan, Y., Kaas, C., Yin, Y., Cecchi,     R., Garnier, S. L., Kelsic, E. D., Schubert, M., et al. (2018).     High-throughput creation and functional profiling of DNA sequence     variant libraries using CRISPR-Cas9 in yeast. Nat Biotechnol 36,     540-546. -   Inaba, H., Greaves, M., and Mullighan, C. G. (2013). Acute     lymphoblastic leukaemia. Lancet 381, 1943-1955. -   Jasin, M., and Haber, J. E. (2016). The democratization of gene     editing: Insights from site-specific cleavage and double-strand     break repair. DNA Repair (Amst) 44, 6-16. -   Kluesner, M. G., Nedveck, D. A., Lahr, W. S., Garbe, J. R.,     Abrahante, J. E., Webber, B. R., and Moriarity, B. S. (2018). EditR:     A Method to Quantify Base Editing from Sanger Sequencing. CRISPR J     1, 239-250. -   Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., and     Liu, D. R. (2016). Programmable editing of a target base in genomic     DNA without double-stranded DNA cleavage. Nature 533, 420-424. -   Komor, A. C., Zhao, K. T., Packer, M. S., Gaudelli, N. M.,     Waterbury, A. L., Koblan, L. W., Kim, Y. B., Badran, A. H., and     Liu, D. R. (2017). Improved base excision repair inhibition and     bacteriophage Mu Gam protein yields C:G-to-T:A base editors with     higher efficiency and product purity. Sci Adv 3, eaao4774. -   Leenay, R. T., Aghazadeh, A., Hiatt, J., Tse, D., Roth, T. L.,     Apathy, R., Shifrut, E., Hultquist, J. F., Krogan, N., Wu, Z., et     al. (2019). Large dataset enables prediction of repair after     CRISPR-Cas9 editing in primary T cells. Nature biotechnology 37,     1034-1037. -   Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks,     E., Fennell, T., O'Donnell-Luria, A. H., Ware, J. S., Hill, A. J.,     Cummings, B. B., et al. (2016). Analysis of protein-coding genetic     variation in 60,706 humans. Nature 536, 285-291. -   Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G.,     Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore,     S., et al. (2005). Activating mutation in the tyrosine kinase JAK2     in polycythemia vera, essential thrombocythemia, and myeloid     metaplasia with myelofibrosis. Cancer Cell 7, 387-397. -   Levy, J. M., Yeh, W. H., Pendse, N., Davis, J. R., Hennessey, E.,     Butcher, R., Koblan, L. W., Comander, J., Liu, Q., and Liu, D. R.     (2020). Cytosine and adenine base editing of the brain, liver,     retina, heart and skeletal muscle of mice via adeno-associated     viruses. Nat Biomed Eng 4, 97-110. -   Lindsay, H., Burger, A., Biyong, B., Felker, A., Hess, C., Zaugg,     J., Chiavacci, E., Anders, C., Jinek, M., Mosimann, C., et al.     (2016). CrispRVariants charts the mutation spectrum of genome     engineering experiments. Nat Biotechnol 34, 701-702. -   Liu, Z., Lu, Z., Yang, G., Huang, S., Li, G., Feng, S., Liu, Y., Li,     J., Yu, W., Zhang, Y., et al. (2018). Efficient generation of mouse     models of human diseases via ABE- and BE-mediated base editing. Nat     Commun 9, 2338. -   Lundin, S., Jemt, A., Terje-Hegge, F., Foam, N., Pettersson, E.,     Kaller, M., Wirta, V., Lexow, P., and Lundeberg, J. (2015).     Endonuclease specificity and sequence dependence of type IIS     restriction enzymes. PLoS One 10, e0117059. -   Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J.     E., Norville, J. E., and Church, G. M. (2013). RNA-guided human     genome engineering via Cas9. Science 339, 823-826. -   Mashal, R. D., Koontz, J., and Sklar, J. (1995). Detection of     mutations by cleavage of DNA heteroduplexes with bacteriophage     resolvases. Nat Genet 9, 177-183. -   McClellan, J., and King, M. C. (2010). Genetic heterogeneity in     human disease. Cell 141, 210-217. -   Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R.,     Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A.     M., et al. (2010). Physiological Jak2V617F expression causes a     lethal myeloproliferative neoplasm with differential effects on     hematopoietic stem and progenitor cells. Cancer Cell 17, 584-596. -   Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G.,     Abate, F., Ambesi-Impiombato, A., Sanchez-Martin, M., Carpenter, Z.,     Penson, A., Perez-Garcia, A., et al. (2016). Mutational landscape,     clonal evolution patterns, and role of RAS mutations in relapsed     acute lymphoblastic leukemia. Proc Natl Acad Sci USA 113,     11306-11311. -   Pathania, S., Bade, S., Le Guillou, M., Burke, K., Reed, R.,     Bowman-Colin, C., Su, Y., Ting, D. T., Polyak, K., Richardson, A.     L., et al. (2014). BRCA1 haploinsufficiency for replication stress     suppression in primary cells. Nature communications 5, 5496. -   Paulsen, B. S., Mandal, P. K., Frock, R. L., Boyraz, B., Yadav, R.,     Upadhyayula, S., Gutierrez-Martinez, P., Ebina, W., Fasth, A.,     Kirchhausen, T., et al. (2017). Ectopic expression of RAD52 and     dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome     editing. Nat Biomed Eng 1, 878-888. -   Pinello, L., Canver, M. C., Hoban, M. D., Orkin, S. H., Kohn, D. B.,     Bauer, D. E., and Yuan, G. C. (2016). Analyzing CRISPR     genome-editing experiments with CRISPResso. Nature biotechnology 34,     695-697. -   Qiu, P., Shandilya, H., D'Alessio, J. M., O'Connor, K., Durocher,     J., and Gerard, G. F. (2004). Mutation detection using Surveyor     nuclease. Biotechniques 36, 702-707. -   Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., and     Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system.     Nature protocols 8, 2281-2308. -   Rees, H. A., and Liu, D. R. (2018). Base editing: precision     chemistry on the genome and transcriptome of living cells. Nat Rev     Genet 19, 770-788. -   Roy, K. R., Smith, J. D., Vonesch, S. C., Lin, G., Tu, C. S.,     Lederer, A. R., Chu, A., Suresh, S., Nguyen, M., Horecka, J., et al.     (2018). Multiplexed precision genome editing with trackable genomic     barcodes in yeast. Nat Biotechnol 36, 512-520. -   Ryu, S. M., Koo, T., Kim, K., Lim, K., Baek, G., Kim, S. T., Kim, H.     S., Kim, D. E., Lee, H., Chung, E., et al. (2018). Adenine base     editing in mouse embryos and an adult mouse model of Duchenne     muscular dystrophy. Nature biotechnology 36, 536-539. -   Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C.     S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., et al.     (2011). BRCA1 tumor suppression depends on BRCT phosphoprotein     binding, but not its E3 ligase activity. Science 334, 525-528. -   Shen, M. W., Arbab, M., Hsu, J. Y., Worstell, D., Culbertson, S. J.,     Krabbe, O., Cassa, C. A., Liu, D. R., Gifford, D. K., and     Sherwood, R. I. (2018). Predictable and precise template-free CRISPR     editing of pathogenic variants. Nature 563, 646-651. -   Song, C. Q., Jiang, T., Richter, M., Rhym, L. H., Koblan, L. W.,     Zafra, M. P., Schatoff, E. M., Doman, J. L., Cao, Y., Dow, L. E., et     al. (2020). Adenine base editing in an adult mouse model of     tyrosinaemia. Nat Biomed Eng 4, 125-130. -   Tan, S. L. W., Chadha, S., Liu, Y., Gabasova, E., Perera, D., Ahmed,     K., Constantinou, S., Renaudin, X., Lee, M., Aebersold, R., et al.     (2017). A Class of Environmental and Endogenous Toxins Induces BRCA2     Haploinsufficiency and Genome Instability. Cell 169, 1105-1118     e1115. -   Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M.,     Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F.,     Kastenhuber, E. R., Weissmueller, S., et al. (2014). p53-dependent     Nestin regulation links tumor suppression to cellular plasticity in     liver cancer. Cell 158, 579-592. -   Tzoneva, G., Dieck, C. L., Oshima, K., Ambesi-Impiombato, A.,     Sanchez-Martin, M., Madubata, C. J., Khiabanian, H., Yu, J.,     Waanders, E., lacobucci, I., et al. (2018). Clonal evolution     mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.     Nature 553, 511-514. -   Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H.,     Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J.     M., Tallman, M. S., et al. (2013). Activating mutations in the NT5C2     nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat     Med 19, 368-371. -   van Overbeek, M., Capurso, D., Carter, M. M., Thompson, M. S.,     Frias, E., Russ, C., Reece-Hoyes, J. S., Nye, C., Gradia, S., Vidal,     B., et al. (2016). DNA Repair Profiling Reveals Nonrandom Outcomes     at Cas9-Mediated Breaks. Mol Cell 63, 633-646. -   Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F.,     Pogliano, C. B., Allegri, G., Fingerhut, R., Haberle, J., Matos, J.,     Robinson, M. D., et al. (2018). Treatment of a metabolic liver     disease by in vivo genome base editing in adult mice. Nat Med 24,     1519-1525. -   Wang, L., Xue, W., Yan, L., Li, X., Wei, J., Chen, M., Wu, J., Yang,     B., Yang, L., and Chen, J. (2017). Enhanced base editing by     co-expression of free uracil DNA glycosylase inhibitor. Cell Res 27,     1289-1292. -   Yeh, W. H., Chiang, H., Rees, H. A., Edge, A. S. B., and Liu, D. R.     (2018). In vivo base editing of post-mitotic sensory cells. Nature     communications 9, 2184. -   Yin, H., Song, C. Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q.,     Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016).     Therapeutic genome editing by combined viral and non-viral delivery     of CRISPR system components in vivo. Nature biotechnology 34,     328-333. -   Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe,     M., Koteliansky, V., Sharp, P. A., Jacks, T., and Anderson, D. G.     (2014). Genome editing with Cas9 in adult mice corrects a disease     mutation and phenotype. Nature biotechnology 32, 551-553. -   Zafra, M. P., Schatoff, E. M., Katti, A., Foronda, M., Breinig, M.,     Schweitzer, A. Y., Simon, A., Han, T., Goswami, S., Montgomery, E.,     et al. (2018). Optimized base editors enable efficient editing in     cells, organoids and mice. Nature biotechnology 36, 888-893. -   Zhang, J., Li, J., Saucier, J. B., Feng, Y., Jiang, Y., Sinson, J.,     McCombs, A. K., Schmitt, E. S., Peacock, S., Chen, S., et al.     (2019). Non-invasive prenatal sequencing for multiple Mendelian     monogenic disorders using circulating cell-free fetal DNA. Nat Med     25, 439-447.

All documents cited in this application are hereby incorporated by reference as if recited in full herein.

Although illustrative embodiments of the present disclosure have been described herein, it should be understood that the disclosure is not limited to those described, and that various other changes or modifications may be made by one skilled in the art without departing from the scope or spirit of the disclosure. 

What is claimed is:
 1. A method for detecting a genetic modification in a DNA sequence of interest, comprising the steps of: (a) amplifying the DNA sequence of interest using a specially designed Type IIS restriction enzyme-tagging primer, comprising: (i) obtaining the DNA sequence of interest from a biological sample; (ii) synthesizing the Type IIS restriction enzyme-tagging primer based on the DNA sequence of interest; (iii) amplifying the DNA sequence of interest using the Type IIS restriction enzyme-tagging primer and a reverse primer; and (iv) purifying a Type IIS restriction enzyme-tagged amplicon; (b) digesting the Type IIS restriction enzyme-tagged amplicon with the Type IIS restriction enzyme; (c) isolating the smaller DNA fragment containing the genetic modification exposed in a 3′ single-stranded overhang; (d) capturing the genetic modification, comprising: (i) preparing a library of 16 DNA adaptors, wherein each DNA adaptor comprises one strand with sequence of 5′-CTGGGGCACGGGTAAGAAGCATTCTGTCTCTCTTCTAAGAATTCGAG CTCGGTACCCG-3′ (SEQ ID NO: 230); and one complementary strand with sequence of 5′-CGGGTACCGAGCTCGAATTCTTAGAAGAGAGACAGAATGCTTCTTAC CCGTGCCCCAGNN-3′ with “N” corresponding to A, T, G or C (SEQ ID NOs: 231-246), and wherein each DNA adaptor has a different “NN”; (ii) incubating the isolated smaller DNA fragment containing the 3′ overhang with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (e) amplifying the ligated product to detect the presence of the genetic modification, wherein the DNA sequence of interest is a genomic locus or corresponds to a genomic locus of an RNA virus variant.
 2. The method of claim 1, wherein the DNA sequence of interest corresponds to a genomic locus of an RNA virus variant, and wherein obtaining the DNA sequence of interest comprises obtaining the RNA sequence from the RNA virus variant and converting it to the corresponding DNA sequence by reverse transcription PCR (RT-PCR).
 3. The method of claim 2, wherein the RNA virus is SARS-CoV-2.
 4. The method of claim 1, wherein the Type IIS restriction enzyme is selected from AcuI, BpmI, BpuEI, BsgI, MmeI and NmeAIII.
 5. The method of claim 4, wherein the Type IIS restriction enzyme is AcuI.
 6. The method of claim 1, wherein the Type IIS restriction enzyme-tagging primer is an oligonucleotide comprising: (a) a non-complementary handle sequence positioned on the 5′ side; (b) a complementary sequence of the genomic locus of interest on the 5′ side; (c) a recognition motif of the Type IIS restriction enzyme that is positioned at a predicted distance from its cleavage site to generate the genomic signature of interest; and (d) a complementary sequence of the genomic locus of interest on the 3′ side.
 7. A kit for detecting a genetic modification of interest, comprising a specially designed Type IIS restriction enzyme-tagging primer according to claim 6, and a library of DNA adaptors according to claim 1, packaged together with instructions for its use.
 8. The method of claim 5, wherein the AcuI-tagging primer is an oligonucleotide comprising: (a) a non-complementary handle sequence positioned on the 5′ side; and (b) a complementary sequence of the genomic locus of interest containing an AcuI motif (5′-CTGAAG-3′) positioned 14 bp upstream from the genomic locus of interest.
 9. The method of claim 8, wherein the reverse primer is positioned at more than 100 bp downstream of the genomic locus of interest.
 10. The method of claim 8, wherein the non-complementary handle sequence is 25 bp.
 11. The method of claim 8, wherein the complementary sequence has the structure of: 5′-N(20)CTGAAGN(14)-3′ or 5′-N(15)CTGAAGN(14)-3′, with “N” corresponding to A, T, G or C, depending on the DNA sequence of the genomic locus of interest.
 12. The method of claim 8, wherein the non-complementary handle sequence is 5′-GCAATTCCTCACGAGACCCGTCCTG-3′ (SEQ ID NO: 3) and the complementary sequence is 5′-N(15)CTGAAGN(14)-3′, with “N” corresponding to A, T, G or C.
 13. A kit for detecting a genetic modification, comprising a specially designed AcuI-tagging primer and a library of DNA adaptors according to claim 1, packaged together with instructions for its use.
 14. A method for quantifying a genomic variant in a biological system, comprising the steps of: (a) obtaining a sample from the biological system; (b) amplifying a DNA sequence of interest using a specially designed AcuI-tagging primer, wherein the DNA sequence of interest is a genomic locus or corresponds to a genomic locus of an RNA virus variant, comprising: (i) obtaining the DNA sequence of interest by (1) genomic extraction or (2) obtaining the RNA sequence from the RNA virus variant and converting it to the corresponding DNA sequence by reverse transcription PCR (RT-PCR); (ii) synthesizing the AcuI-tagging primer based on the DNA sequence of interest; (iii) amplifying the DNA sequence of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged amplicon; (c) digesting the AcuI-tagged amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing the genomic variant of interest produced by the AcuI-digestion; (e) capturing the genomic variant of interest, comprising: (i) preparing the library of DNA adaptors according to claim 1; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; and (f) quantifying the genomic variant and determining its relative abundance.
 15. The method of claim 14, wherein the genomic variant is generated by precision genome editing.
 16. The method of claim 15, wherein the precision genome editing is CRISPER-dependent homology-directed repair, base editing or prime editing.
 17. The method of claim 14, wherein the quantification in step (f) is carried out by quantitative PCR (qPCR).
 18. A method for identifying and quantifying an oncogenic mutation of interest in a biological sample, comprising the steps of: (a) obtaining a biological sample; (b) amplifying a genomic locus of interest using a specially designed AcuI-tagging primer, comprising: (i) extracting DNA of interest; (ii) synthesizing the AcuI-tagging primer based on the genomic locus of interest; (iii) amplifying the genomic locus of interest using the AcuI-tagging primer and a reverse primer; and (iv) purifying an AcuI-tagged genomic amplicon; (c) digesting the AcuI-tagged genomic amplicon with restriction enzyme AcuI; (d) isolating the smaller DNA fragment containing the oncogenic mutation of interest produced by the AcuI-digestion; (e) capturing the genomic signature of interest, comprising: (i) preparing the library of DNA adaptors according to claim 1; (ii) incubating the isolated smaller DNA fragment with the library of DNA adaptors and performing a ligation; and (iii) obtaining a ligated product; (f) amplifying the ligated product to identify the presence of the oncogenic mutation of interest; and (g) quantifying the oncogenic mutation of interest, if present, and determining its frequency.
 19. The method of claim 18, wherein the biological sample is obtained from a cancer animal model, a patient-derived xenograft (PDX), or a human cancer patient sample.
 20. The method of claim 18, wherein the quantification in step (g) is carried out by quantitative PCR (qPCR). 